PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30652743-4	2018	The impact of papaverine on endothelial integrity was studied by measurement of the percentage of vessel"s circumference revealing CD34 endothelial marker.	Papaverine	14-24	CD34 molecule	Homo sapiens	131-135
30397325-6	2018	Treatment with the Pde10a inhibitor papaverine or knockdown of Pde10a ameliorates the deficits observed in the heterozygous cKO mice.	Papaverine	36-46	phosphodiesterase 10A	Mus musculus	19-25
29541234-2	2018	In the present study, papaverine was identified as a RAGE inhibitor using the conversion to small molecules through optimized-peptide strategy drug design system.	Papaverine	22-32	advanced glycosylation end-product specific receptor	Homo sapiens	53-57
29541234-3	2018	Papaverine significantly inhibited RAGE-dependent nuclear factor kappa-B activation driven by high mobility group box-1, a RAGE ligand.	Papaverine	0-10	advanced glycosylation end-product specific receptor	Homo sapiens	35-39
29541234-3	2018	Papaverine significantly inhibited RAGE-dependent nuclear factor kappa-B activation driven by high mobility group box-1, a RAGE ligand.	Papaverine	0-10	high mobility group box 1	Homo sapiens	94-119
29541234-3	2018	Papaverine significantly inhibited RAGE-dependent nuclear factor kappa-B activation driven by high mobility group box-1, a RAGE ligand.	Papaverine	0-10	advanced glycosylation end-product specific receptor	Homo sapiens	123-127
29541234-4	2018	Using RAGE- or dominant-negative RAGE-expressing HT1080 human fibrosarcoma cells, the present study revealed that papaverine suppressed RAGE-dependent cell proliferation and migration dose-dependently.	Papaverine	114-124	advanced glycosylation end-product specific receptor	Homo sapiens	6-10
29541234-4	2018	Using RAGE- or dominant-negative RAGE-expressing HT1080 human fibrosarcoma cells, the present study revealed that papaverine suppressed RAGE-dependent cell proliferation and migration dose-dependently.	Papaverine	114-124	advanced glycosylation end-product specific receptor	Homo sapiens	33-37
29541234-4	2018	Using RAGE- or dominant-negative RAGE-expressing HT1080 human fibrosarcoma cells, the present study revealed that papaverine suppressed RAGE-dependent cell proliferation and migration dose-dependently.	Papaverine	114-124	advanced glycosylation end-product specific receptor	Homo sapiens	33-37
29541234-6	2018	The results of the present study suggested that papaverine could inhibit RAGE, and provided novel insights into the field of RAGE biology, particularly anticancer therapies.	Papaverine	48-58	advanced glycosylation end-product specific receptor	Homo sapiens	73-77
29541234-6	2018	The results of the present study suggested that papaverine could inhibit RAGE, and provided novel insights into the field of RAGE biology, particularly anticancer therapies.	Papaverine	48-58	advanced glycosylation end-product specific receptor	Homo sapiens	125-129
28966237-6	2017	In the current study, we investigated the inhibitory effects of five gastrointestinal drugs, namely loperamide, oxethazaine, papaverine, pirenzepine, and trimebutine, on CYP activities in human liver microsomes.	Papaverine	125-135	peptidylprolyl isomerase G	Homo sapiens	170-173
29040550-7	2017	Treatment of Ndufs4 KO mice with papaverine, zolpidem, and rapamycin-suppressed inflammation, prevented cell death, and protected from vision loss.	Papaverine	33-43	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	13-19
29040550-8	2017	Thus, in the Ndufs4 KO mouse model of mitochondrial optic neuropathy, papaverine and zolpidem provided significant protection from multiple pathophysiological features, and as approved drugs in wide human use could be considered for the novel indication of human optic neuropathy.	Papaverine	70-80	NADH:ubiquinone oxidoreductase core subunit S4	Mus musculus	13-19
27879007-1	2017	Drotaverine (also known as dihydroperparine or No-Spa  ) is an antispasmodic drug closely related to papaverin.	Papaverine	101-110	surfactant protein A2	Homo sapiens	50-53
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Papaverine	95-105	taste 2 receptor member 10	Homo sapiens	122-131
29311514-5	2018	From taste sensor measurements, diphenidol, haloperidol, diphenhydramine, dextromethorphan and papaverine, all ligands of hTAS2R 10 and/or hTAS2R14, were predicted to express strong bitterness, surpassing that of quinine.	Papaverine	95-105	taste 2 receptor member 14	Homo sapiens	139-147
28362714-9	2017	RESULTS: Iloprost, PGE1, and papaverine similarly reduced vascular tone to 20% to 30% of ET-1-induced wall tension.	Papaverine	29-39	endothelin 1	Homo sapiens	89-93
28966237-9	2017	CYP3A4 activity was markedly inhibited by trimebutine, papaverine, and oxethazaine.	Papaverine	55-65	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
26700561-7	2016	The receptor-mediated enhancement of Kv7.5 currents was mimicked by pharmacological agents that increase [cAMP] (forskolin, rolipram, 3-isobutyl-1-methylxanthine, and papaverine) or mimic cAMP (8-bromo-cAMP); the 2- to 4-fold PKA-dependent enhancement of currents was also observed with exogenously expressed Kv7.5 channels.	Papaverine	167-177	potassium voltage-gated channel subfamily Q member 5	Homo sapiens	37-42
27860455-5	2017	Using different family-specific PDE inhibitors, we showed that in cauda epididymal and ejaculated spermatozoa, the major cAMP-PDE activity was papaverine-sensitive (44.5% and 57.5%, respectively, at 400 nm, papaverine is a specific inhibitor of the PDE10 family).	Papaverine	143-153	cathelicidin-7	Bos taurus	121-125
27860455-5	2017	Using different family-specific PDE inhibitors, we showed that in cauda epididymal and ejaculated spermatozoa, the major cAMP-PDE activity was papaverine-sensitive (44.5% and 57.5%, respectively, at 400 nm, papaverine is a specific inhibitor of the PDE10 family).	Papaverine	207-217	cathelicidin-7	Bos taurus	121-125
27860455-8	2017	Using papaverine, we showed that it promotes tyrosine phosphorylation of sperm proteins, phosphorylation of Erk1 and Erk2, and Ca2+ release from Ca2+ store.	Papaverine	6-16	mitogen-activated protein kinase 3	Bos taurus	108-112
27860455-8	2017	Using papaverine, we showed that it promotes tyrosine phosphorylation of sperm proteins, phosphorylation of Erk1 and Erk2, and Ca2+ release from Ca2+ store.	Papaverine	6-16	mitogen-activated protein kinase 1	Bos taurus	117-121
28365943-0	2017	Papaverine selectively inhibits human prostate cancer cell (PC-3) growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of NF-kappaB/PI3K/Akt signalling pathway.	Papaverine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	159-168
28365943-0	2017	Papaverine selectively inhibits human prostate cancer cell (PC-3) growth by inducing mitochondrial mediated apoptosis, cell cycle arrest and downregulation of NF-kappaB/PI3K/Akt signalling pathway.	Papaverine	0-10	AKT serine/threonine kinase 1	Homo sapiens	174-177
28365943-7	2017	Papaverine induced a dose-dependent reduction in the expression levels of Blc-2 proteins and a dose-dependent increase in the expression levels of Bax protein.	Papaverine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	147-150
28365943-9	2017	Papaverine treatment also led to a dose-dependent downregulation of PI3K and phospho-Akt expression.	Papaverine	0-10	AKT serine/threonine kinase 1	Homo sapiens	85-88
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	BCL2 apoptosis regulator	Homo sapiens	212-217
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	BCL2 associated X, apoptosis regulator	Homo sapiens	219-222
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	BH3 interacting domain death agonist	Homo sapiens	224-227
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	X-linked inhibitor of apoptosis	Homo sapiens	229-233
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	cytochrome c, somatic	Homo sapiens	238-250
28365943-10	2017	CONCLUSION: Papaverine showed selective antitumor properties against PC-3 human prostate cancer cells by inducing early and late apoptosis, sub-G1 cell cycle arrest, modulation of apoptosis-related proteins like Bcl-2, Bax, Bid, XIAP and cytochrome C along with downregulation of NFkB, PI3K/Akt signalling pathway.	Papaverine	12-22	AKT serine/threonine kinase 1	Homo sapiens	291-294
27565610-5	2016	Using different family-specific PDE inhibitors, we showed that in seminal plasma, the major cAMP-PDE activity was papaverine sensitive (47.5%).	Papaverine	114-124	phosphodiesterase 10A	Bos taurus	32-35
27565610-5	2016	Using different family-specific PDE inhibitors, we showed that in seminal plasma, the major cAMP-PDE activity was papaverine sensitive (47.5%).	Papaverine	114-124	phosphodiesterase 10A	Bos taurus	97-100
27136356-0	2016	Papaverine Prevents Vasospasm by Regulation of Myosin Light Chain Phosphorylation and Actin Polymerization in Human Saphenous Vein.	Papaverine	0-10	myosin heavy chain 14	Homo sapiens	47-53
27136356-3	2016	We hypothesized that papaverine reduces force by decreasing intracellular calcium concentrations ([Ca2+]i) and myosin light chain phosphorylation, and increasing actin depolymerization via regulation of actin regulatory protein phosphorylation.	Papaverine	21-31	myosin heavy chain 14	Homo sapiens	111-117
27136356-7	2016	Pre-treatment with papaverine completely inhibited norepinephrine-induced force generation, blocked increases in [Ca2+]i and led to a decrease in the phosphorylation of myosin light chain.	Papaverine	19-29	myosin heavy chain 14	Homo sapiens	169-175
27136356-8	2016	Papaverine pre-treatment also led to increased phosphorylation of the heat shock-related protein 20 (HSPB6) and the vasodilator stimulated phosphoprotein (VASP), as well as decreased filamentous actin (F-actin) levels suggesting depolymerization of actin.	Papaverine	0-10	heat shock protein family B (small) member 6	Homo sapiens	101-106
27136356-8	2016	Papaverine pre-treatment also led to increased phosphorylation of the heat shock-related protein 20 (HSPB6) and the vasodilator stimulated phosphoprotein (VASP), as well as decreased filamentous actin (F-actin) levels suggesting depolymerization of actin.	Papaverine	0-10	vasodilator stimulated phosphoprotein	Homo sapiens	116-153
27136356-8	2016	Papaverine pre-treatment also led to increased phosphorylation of the heat shock-related protein 20 (HSPB6) and the vasodilator stimulated phosphoprotein (VASP), as well as decreased filamentous actin (F-actin) levels suggesting depolymerization of actin.	Papaverine	0-10	vasodilator stimulated phosphoprotein	Homo sapiens	155-159
27136356-9	2016	CONCLUSIONS: These results suggest that papaverine-induced force inhibition of HSV involves [Ca2+]i-mediated inhibition of myosin light chain phosphorylation and actin regulatory protein phosphorylation-mediated actin depolymerization.	Papaverine	40-50	myosin heavy chain 14	Homo sapiens	123-129
27136356-10	2016	Thus, papaverine induces sustained inhibition of contraction of HSV by the modulation of both myosin cross-bridge formation and actin cytoskeletal dynamics and is a pharmacological alternative to high pressure distention to prevent vasospasm.	Papaverine	6-16	myosin heavy chain 14	Homo sapiens	94-100
26700561-7	2016	The receptor-mediated enhancement of Kv7.5 currents was mimicked by pharmacological agents that increase [cAMP] (forskolin, rolipram, 3-isobutyl-1-methylxanthine, and papaverine) or mimic cAMP (8-bromo-cAMP); the 2- to 4-fold PKA-dependent enhancement of currents was also observed with exogenously expressed Kv7.5 channels.	Papaverine	167-177	potassium voltage-gated channel subfamily Q member 5	Homo sapiens	309-314
26205238-10	2015	Combining the IBMX-resin with in-solution competition with the available more selective PDE inhibitors, cilostamide and papaverine, allowed us to selectively probe the interactome of PDE3A in HeLa cells.	Papaverine	120-130	phosphodiesterase 3A	Homo sapiens	183-188
22414727-6	2012	In this article, we report the successful identification of six approved drugs out of the Drugbank as FXR modulators (ketoconazole, pentamidine, dobutamine, imatinib, papaverine and montelukast) by using a SOM for screening of the DrugBank database.	Papaverine	167-177	nuclear receptor subfamily 1 group H member 4	Homo sapiens	102-105
25762659-5	2015	By developing a novel assay to label nascent peptidic chains, we show that the rpS6 phosphorylation induced in striatonigral MSNs by d-amph, as well as in striatopallidal MSNs by the antipsychotic haloperidol or in both subtypes by papaverine, is not correlated with the translation of global or 5" terminal oligopyrimidine tract mRNAs.	Papaverine	232-242	ribosomal protein S6	Mus musculus	79-83
23722687-10	2013	Compared with propranolol, the relative intensities of six free drugs (berbamine, tetrandrine, papaverine, reserpine, brucine and tetrahydropalmatine) clearly faded after the addition of calmodulin, indicating that they can bind with CaM.	Papaverine	95-105	calmodulin 1	Homo sapiens	187-197
25173217-2	2014	The selective adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), increased the frequency, but not the amplitude of spontaneous inhibitory post-synaptic currents (IPSCs) in the presence of the dopamine D1 receptor agonist SKF 38393 (SKF) and phosphodiesterase 10A inhibitors (papaverine or AE90074).	Papaverine	308-318	adenosine A1 receptor	Mus musculus	4-40
25004204-7	2014	Abeta caused reduced dilation to papaverine.	Papaverine	33-43	amyloid beta precursor protein	Homo sapiens	0-5
25111025-3	2014	Although this alkaloid does not directly interact with telomeric sequences, papaverine inhibits telomerase through down-regulation of hTERT, which was analysed using thermal FRET and qRT-PCR, respectively.	Papaverine	76-86	telomerase reverse transcriptase	Homo sapiens	134-139
24523141-3	2014	VEGF-induced and PA-induced increase of EB extravasation was further increased after combining VEGF with PA infusion.	Papaverine	17-19	vascular endothelial growth factor A	Rattus norvegicus	95-99
24523141-3	2014	VEGF-induced and PA-induced increase of EB extravasation was further increased after combining VEGF with PA infusion.	Papaverine	105-107	vascular endothelial growth factor A	Rattus norvegicus	0-4
24523141-6	2014	In addition, after VEGF and PA infusion, the results of radioimmunoassay, Western blot, and enzyme-linked immunosorbent assay (ELISA) revealed a significant increase in expression levels of cGMP and protein kinase G-1 (PKG-1) and the activation of nuclear factor-kappaB (NF-kappaB) p65.	Papaverine	28-30	synaptotagmin 1	Rattus norvegicus	282-285
24414229-0	2014	Papaverine increases human serum albumin glycation.	Papaverine	0-10	albumin	Homo sapiens	33-40
23691025-5	2013	Of interest, we found increased expression of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA restored cAMP/PKA signaling.	Papaverine	135-145	phosphodiesterase 10A	Homo sapiens	46-67
23691025-5	2013	Of interest, we found increased expression of phosphodiesterase 10A (PDE10A) in HPRT-deficient cell lines and that the PDE10 inhibitor papaverine and PDE10A siRNA restored cAMP/PKA signaling.	Papaverine	135-145	phosphodiesterase 10A	Homo sapiens	69-75
21816164-0	2011	The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.	Papaverine	22-32	phosphodiesterase 10A	Rattus norvegicus	4-10
21856317-8	2012	Selected doses of the four PDEIs evaluated (PDE2: BAY 60-7550; PDE4: rolipram; PDE5: sildenafil; PDE10A: papaverine) were able to significantly attenuate this cognitive deficit in EDS performance.	Papaverine	105-115	phosphodiesterase 2A	Rattus norvegicus	44-48
21856317-8	2012	Selected doses of the four PDEIs evaluated (PDE2: BAY 60-7550; PDE4: rolipram; PDE5: sildenafil; PDE10A: papaverine) were able to significantly attenuate this cognitive deficit in EDS performance.	Papaverine	105-115	phosphodiesterase 10A	Rattus norvegicus	97-103
22001259-7	2012	The ROCE was inhibited by forskolin and papaverine to activate the cAMP/PKA pathway, whereas it was potentiated by Rp-8-bromoadenosine-cAMP sodium salt, a PKA inhibitor.	Papaverine	40-50	cathelicidin antimicrobial peptide	Homo sapiens	67-71
22001259-8	2012	The inhibitory effects of forskolin and papaverine were partially cancelled by replacing Ser28 (TRPC6(S28A)) but not Thr69 (TRPC6(T69A)) of TRPC6 with alanine.	Papaverine	40-50	transient receptor potential cation channel subfamily C member 6	Homo sapiens	96-101
21816164-0	2011	The PDE10A inhibitor, papaverine, differentially activates ERK in male and female rat striatal slices.	Papaverine	22-32	Eph receptor B1	Rattus norvegicus	59-62
21816164-3	2011	In particular, papaverine, a selective PDE10A inhibitor has been shown to activate/phosphorylate ERK in striatum.	Papaverine	15-25	phosphodiesterase 10A	Rattus norvegicus	39-45
21816164-3	2011	In particular, papaverine, a selective PDE10A inhibitor has been shown to activate/phosphorylate ERK in striatum.	Papaverine	15-25	Eph receptor B1	Rattus norvegicus	97-100
21816164-4	2011	We used acute rat striatal slices to further characterize the effects of papaverine on ERK activation/phosphorylation in D1- and D2-responsive striatal neurons.	Papaverine	73-83	Eph receptor B1	Rattus norvegicus	87-90
21816164-5	2011	Incubation of striatal slices from male rats with papaverine increased the levels of phospho-ERK1/2 (p-ERK), an effect enhanced with a D1 agonist or a D2 antagonist, but decreased with a D1 receptor antagonist or a D2 receptor agonist.	Papaverine	50-60	mitogen activated protein kinase 3	Rattus norvegicus	93-99
21816164-5	2011	Incubation of striatal slices from male rats with papaverine increased the levels of phospho-ERK1/2 (p-ERK), an effect enhanced with a D1 agonist or a D2 antagonist, but decreased with a D1 receptor antagonist or a D2 receptor agonist.	Papaverine	50-60	Eph receptor B1	Rattus norvegicus	93-96
21816164-6	2011	Papaverine-induced increase in p-ERK was localized in striatal neurons receiving D1-enriched presynaptic terminals, as well as in postsynaptic D2-enriched neurons in striatal slices.	Papaverine	0-10	Eph receptor B1	Rattus norvegicus	33-36
21816164-8	2011	In striatal slices prepared from ovariectomized female rats, papaverine treatment stimulated ERK1/2 phosphorylation to levels similar to those in slices from male rats.	Papaverine	61-71	mitogen activated protein kinase 3	Rattus norvegicus	93-99
21920746-0	2011	New PDE4 inhibitors based on pharmacophoric similarity between papaverine and tofisopam.	Papaverine	63-73	phosphodiesterase 4A	Homo sapiens	4-8
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	0-49	phosphodiesterase 10A	Rattus norvegicus	108-114
20683758-1	2011	This study was performed to determine whether low frequency ultrasound (LFU) irradiation, Papaverine (PA) infusion and combination LFU irradiation with PA infusion opened the blood-tumor barrier (BTB) by affecting tight junctions (TJ)-associated proteins zonula occluden-1 (ZO-1), occludin and caludin-5.	Papaverine	152-154	tight junction protein 1	Rattus norvegicus	214-278
20683758-1	2011	This study was performed to determine whether low frequency ultrasound (LFU) irradiation, Papaverine (PA) infusion and combination LFU irradiation with PA infusion opened the blood-tumor barrier (BTB) by affecting tight junctions (TJ)-associated proteins zonula occluden-1 (ZO-1), occludin and caludin-5.	Papaverine	152-154	occludin	Rattus norvegicus	281-289
20683758-2	2011	In a rat brain glioma model, we found that the mRNA and protein expression levels of ZO-1, occludin and claudin-5 were decreased by LFU irradiation and PA infusion.	Papaverine	152-154	tight junction protein 1	Rattus norvegicus	85-89
20683758-2	2011	In a rat brain glioma model, we found that the mRNA and protein expression levels of ZO-1, occludin and claudin-5 were decreased by LFU irradiation and PA infusion.	Papaverine	152-154	occludin	Rattus norvegicus	91-99
20683758-2	2011	In a rat brain glioma model, we found that the mRNA and protein expression levels of ZO-1, occludin and claudin-5 were decreased by LFU irradiation and PA infusion.	Papaverine	152-154	claudin 5	Rattus norvegicus	104-113
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	16-18	tight junction protein 1	Rattus norvegicus	39-43
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	16-18	occludin	Rattus norvegicus	45-53
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	16-18	claudin 5	Rattus norvegicus	58-67
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	127-129	tight junction protein 1	Rattus norvegicus	39-43
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	127-129	occludin	Rattus norvegicus	45-53
20683758-3	2011	LFU-induced and PA-induced decrease of ZO-1, occludin and claudin-5 was further decreased after combining LFU irradiation with PA infusion.	Papaverine	127-129	claudin 5	Rattus norvegicus	58-67
20683758-7	2011	Significantly down-regulated expression levels of ZO-1, occludin and claudin-5 might be one of the molecular mechanisms of combining LFU and PA enhancing the permeability of BTB.	Papaverine	141-143	tight junction protein 1	Rattus norvegicus	50-54
20683758-7	2011	Significantly down-regulated expression levels of ZO-1, occludin and claudin-5 might be one of the molecular mechanisms of combining LFU and PA enhancing the permeability of BTB.	Papaverine	141-143	occludin	Rattus norvegicus	56-64
20683758-7	2011	Significantly down-regulated expression levels of ZO-1, occludin and claudin-5 might be one of the molecular mechanisms of combining LFU and PA enhancing the permeability of BTB.	Papaverine	141-143	claudin 5	Rattus norvegicus	69-78
21211516-0	2011	Potentiation of NGF-induced neurite outgrowth in PC12 cells by papaverine: role played by PLC-gamma, IP3 receptors.	Papaverine	63-73	nerve growth factor	Rattus norvegicus	16-19
21211516-4	2011	Papaverine potentiated NGF-induced neurite outgrowth in PC12 cells in a concentration-dependent manner.	Papaverine	0-10	nerve growth factor	Rattus norvegicus	23-26
21211516-6	2011	The potentiation of NGF-induced neurite outgrowth by papaverine was blocked by the PLC-gamma inhibitor U73122.	Papaverine	53-63	nerve growth factor	Rattus norvegicus	20-23
21211516-7	2011	Furthermore, papaverine"s potentiation of NGF-induced neurite outgrowth was also blocked by the co-administration of inositol 1,4,5-trisphosphate (IP(3)) receptor antagonists (xestospongin C and 2-aminoethoxydiphenyl borate (2-APB)) and by reduced expression of IP(3) receptor gene (i.e., itpr1 and itpr3) by siRNA.	Papaverine	13-23	nerve growth factor	Rattus norvegicus	42-45
21211516-7	2011	Furthermore, papaverine"s potentiation of NGF-induced neurite outgrowth was also blocked by the co-administration of inositol 1,4,5-trisphosphate (IP(3)) receptor antagonists (xestospongin C and 2-aminoethoxydiphenyl borate (2-APB)) and by reduced expression of IP(3) receptor gene (i.e., itpr1 and itpr3) by siRNA.	Papaverine	13-23	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	147-162
21211516-7	2011	Furthermore, papaverine"s potentiation of NGF-induced neurite outgrowth was also blocked by the co-administration of inositol 1,4,5-trisphosphate (IP(3)) receptor antagonists (xestospongin C and 2-aminoethoxydiphenyl borate (2-APB)) and by reduced expression of IP(3) receptor gene (i.e., itpr1 and itpr3) by siRNA.	Papaverine	13-23	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	262-276
21211516-7	2011	Furthermore, papaverine"s potentiation of NGF-induced neurite outgrowth was also blocked by the co-administration of inositol 1,4,5-trisphosphate (IP(3)) receptor antagonists (xestospongin C and 2-aminoethoxydiphenyl borate (2-APB)) and by reduced expression of IP(3) receptor gene (i.e., itpr1 and itpr3) by siRNA.	Papaverine	13-23	inositol 1,4,5-trisphosphate receptor, type 1	Rattus norvegicus	289-294
21211516-7	2011	Furthermore, papaverine"s potentiation of NGF-induced neurite outgrowth was also blocked by the co-administration of inositol 1,4,5-trisphosphate (IP(3)) receptor antagonists (xestospongin C and 2-aminoethoxydiphenyl borate (2-APB)) and by reduced expression of IP(3) receptor gene (i.e., itpr1 and itpr3) by siRNA.	Papaverine	13-23	inositol 1,4,5-trisphosphate receptor, type 3	Rattus norvegicus	299-304
21211516-8	2011	Our findings suggest that papaverine could potentiate NGF-induced neurite outgrowth, and that activation of PLC-gamma and IP(3) receptors might be involved in the mechanism underlying papaverine"s potentiation of neurite outgrowth in PC12 cells.	Papaverine	26-36	nerve growth factor	Rattus norvegicus	54-57
21211516-8	2011	Our findings suggest that papaverine could potentiate NGF-induced neurite outgrowth, and that activation of PLC-gamma and IP(3) receptors might be involved in the mechanism underlying papaverine"s potentiation of neurite outgrowth in PC12 cells.	Papaverine	184-194	nerve growth factor	Rattus norvegicus	54-57
21391338-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A (9).	Papaverine	0-49	phosphodiesterase 10A	Rattus norvegicus	108-114
21391338-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A (9).	Papaverine	51-61	phosphodiesterase 10A	Rattus norvegicus	108-114
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	0-49	phosphodiesterase 10A	Rattus norvegicus	176-185
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	0-49	phosphodiesterase 3A	Rattus norvegicus	197-202
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	0-49	phosphodiesterase 4D	Rattus norvegicus	219-224
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	51-61	phosphodiesterase 10A	Rattus norvegicus	108-114
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	51-61	phosphodiesterase 10A	Rattus norvegicus	176-185
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	51-61	phosphodiesterase 3A	Rattus norvegicus	197-202
21563650-3	2011	Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis.	Papaverine	0-10	vascular endothelial growth factor A	Rattus norvegicus	133-167
21391339-7	2004	1-(3,4-Dimethoxybenzyl)-6,7-dimethoxyisoquinoline (papaverine) has been found to be a specific inhibitor of PDE10A with 50% inhibition concentration (IC50) values of 36 nM for PDE10A, 1,300 nM for PDE3A, and 320 nM for PDE4D (9).	Papaverine	51-61	phosphodiesterase 4D	Rattus norvegicus	219-224
21563650-3	2011	Papaverine, a myorelaxant and vasodilatator, and pentoxiphylline, a hemorrheologic agent are used for microcirculation disorders and vascular endothelial growth factor (VEGF) is a stimulator of angiogenesis.	Papaverine	0-10	vascular endothelial growth factor A	Rattus norvegicus	169-173
21372424-3	2011	A harmala alkaloid, harmine, an opium alkaloid, papaverine, and Lycoris alkaloids, lycorine and lycoricidinol, showed TNF-alpha suppressive activities stronger than or comparable to that of a reference polyphenol, butein, in RAW264 cells (IC(50)=4, 10, 2.1, 0.02, and 8 microM, respectively).	Papaverine	48-58	tumor necrosis factor	Mus musculus	118-127
20728510-5	2010	The most obvious attenuation of occludin, claudin-5 and F-actin protein was observed at 1h after papaverine perfusion, companied by a significant decrease in expression levels of PKA protein.	Papaverine	97-107	occludin	Rattus norvegicus	32-40
21039754-10	2011	Moreover, inverse correlations were found between baPWV and Delta%CoD following administration of NTG (endothelium-independent vasodilator) and Delta%CBF following administration of Pa (endothelium-independent vasodilator).	Papaverine	182-184	CCAAT enhancer binding protein zeta	Homo sapiens	144-153
21474921-7	2011	With regard to the physiological role of PDE10A in the pineal gland, the specific PDE10A inhibitor papaverine was seen to enhance the adrenergic stimulation of the second messenger cAMP and cGMP.	Papaverine	99-109	phosphodiesterase 10A	Rattus norvegicus	41-47
21474921-7	2011	With regard to the physiological role of PDE10A in the pineal gland, the specific PDE10A inhibitor papaverine was seen to enhance the adrenergic stimulation of the second messenger cAMP and cGMP.	Papaverine	99-109	phosphodiesterase 10A	Rattus norvegicus	82-88
20728510-0	2010	The modulation of protein kinase A and heat shock protein 70 is involved in the reversible increase of blood-brain tumor barrier permeability induced by papaverine.	Papaverine	153-163	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	18-34
20728510-0	2010	The modulation of protein kinase A and heat shock protein 70 is involved in the reversible increase of blood-brain tumor barrier permeability induced by papaverine.	Papaverine	153-163	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	39-60
20728510-4	2010	The levels of occludin, claudin-5 and F-actin protein in the tumor tissues were down-regulated by papaverine via immunohistochemistry, immunofluorescence assays and Western blot, corresponding to the time-dependent change of the BTB permeability.	Papaverine	98-108	occludin	Rattus norvegicus	14-22
20728510-4	2010	The levels of occludin, claudin-5 and F-actin protein in the tumor tissues were down-regulated by papaverine via immunohistochemistry, immunofluorescence assays and Western blot, corresponding to the time-dependent change of the BTB permeability.	Papaverine	98-108	claudin 5	Rattus norvegicus	24-33
20728510-5	2010	The most obvious attenuation of occludin, claudin-5 and F-actin protein was observed at 1h after papaverine perfusion, companied by a significant decrease in expression levels of PKA protein.	Papaverine	97-107	claudin 5	Rattus norvegicus	42-51
20728510-6	2010	The expression level of HSP70 in the tumor tissues was also progressively increased after papaverine perfusion and reached the maximum at 3h.	Papaverine	90-100	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	24-29
20728510-7	2010	The results demonstrate that the reversible openning of BTB mediated by papaverine may be associated with the functional combination between PKA and HSP70.	Papaverine	72-82	protein kinase cAMP-activated catalytic subunit alpha	Rattus norvegicus	141-144
20728510-7	2010	The results demonstrate that the reversible openning of BTB mediated by papaverine may be associated with the functional combination between PKA and HSP70.	Papaverine	72-82	heat shock protein family A (Hsp70) member 1B	Rattus norvegicus	149-154
19622871-0	2009	Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure.	Papaverine	138-148	activation induced cytidine deaminase	Homo sapiens	40-43
20447563-0	2010	Carbon-11 labeled papaverine as a PET tracer for imaging PDE10A: radiosynthesis, in vitro and in vivo evaluation.	Papaverine	18-28	phosphodiesterase 10A	Rattus norvegicus	57-63
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	0-10	phosphodiesterase 10A	Rattus norvegicus	147-156
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	0-10	phosphodiesterase 3A	Rattus norvegicus	168-173
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	0-10	phosphodiesterase 4D	Rattus norvegicus	189-194
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	0-10	phosphodiesterase 10A	Rattus norvegicus	147-153
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	12-61	phosphodiesterase 10A	Rattus norvegicus	147-156
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	12-61	phosphodiesterase 3A	Rattus norvegicus	168-173
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	12-61	phosphodiesterase 4D	Rattus norvegicus	189-194
20447563-1	2010	Papaverine, 1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline, a specific inhibitor of phosphodiesterase (PDE) 10A with IC(50) values of 36 nM for PDE10A, 1,300 nM for PDE3A and 320 nM for PDE4D, has served as a useful pharmaceutical tool to study the physiological role of PDE10A.	Papaverine	12-61	phosphodiesterase 10A	Rattus norvegicus	147-153
20447563-2	2010	Here, we report the radiosynthesis of [(11)C]papaverine and the in vitro and in vivo evaluation of [(11)C]papaverine as a potential positron emission tomography (PET) radiotracer for imaging PDE10A in the central nervous system (CNS).	Papaverine	106-116	phosphodiesterase 10A	Rattus norvegicus	191-197
20447563-9	2010	Analogs of papaverine having a higher potency for inhibiting PDE10A and improved pharmacokinetic properties will be necessary for imaging this enzyme with PET.	Papaverine	11-21	phosphodiesterase 10A	Rattus norvegicus	61-67
20019334-7	2010	Responses to 10 micromol/L papaverine, a direct smooth muscle dilator, were impaired with the HM/LF diet in wild-type mice (30 + or - 3 versus 45 + or - 5%; P<0.05) but not DDAH1 Tg mice (45 + or - 7 versus 48 + or - 6%).	Papaverine	27-37	dimethylarginine dimethylaminohydrolase 1	Mus musculus	176-181
20407482-4	2010	Papaverine has been used as a pharmacological tool to establish the possible clinical use of PDE10A inhibitors as antipsychotics.	Papaverine	0-10	phosphodiesterase 10A	Rattus norvegicus	93-99
19622871-0	2009	Cross-linking of protein crystals as an aid in the generation of binary protein-ligand crystal complexes, exemplified by the human PDE10a-papaverine structure.	Papaverine	138-148	phosphodiesterase 10A	Homo sapiens	131-137
19622871-4	2009	Using crystals of human phosphodiesterase 10a (hPDE10a) as an example of such a challenging crystallographic system, the structure of the complex with papaverine was obtained to 2.8 A resolution using protein crystals cross-linked by glutaraldehyde prior to soaking of the ligand.	Papaverine	151-161	phosphodiesterase 10A	Homo sapiens	24-45
19622871-4	2009	Using crystals of human phosphodiesterase 10a (hPDE10a) as an example of such a challenging crystallographic system, the structure of the complex with papaverine was obtained to 2.8 A resolution using protein crystals cross-linked by glutaraldehyde prior to soaking of the ligand.	Papaverine	151-161	phosphodiesterase 10A	Homo sapiens	47-54
19387141-9	2009	There was a significant decrease in flap ischemia in the papaverine-treated group compared with both BTX and saline (P < 0.01).	Papaverine	57-67	cholinergic receptor nicotinic alpha 7 subunit	Rattus norvegicus	101-104
19066855-0	2009	Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine.	Papaverine	75-85	phosphodiesterase 10A	Rattus norvegicus	57-63
19066855-4	2009	Previous studies were controversial, showing antipsychotic-like profiles in measures of PPI for the preferential PDE10A inhibitor papaverine (PAP) but not the novel PDE10A inhibitor TP-10.	Papaverine	130-140	phosphodiesterase 10A	Rattus norvegicus	113-119
19336898-0	2009	Docking simulations and in vitro assay unveil potent inhibitory action of papaverine against protein tyrosine phosphatase 1B.	Papaverine	74-84	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	93-124
19336898-2	2009	The investigation included simulated docking experiments to fit papaverine into the binding pocket of h-PTP 1B.	Papaverine	64-74	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	104-110
19336898-3	2009	Papaverine was found to readily dock within the binding pocket of h-PTP 1B in a low energy orientation via an optimal set of attractive interactions.	Papaverine	0-10	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	68-74
19336898-4	2009	Experimentally, papaverine illustrated potent in vitro inhibitory effect against recombinant h-PTP 1B (IC(50)=1.20 microM).	Papaverine	16-26	protein tyrosine phosphatase non-receptor type 1	Homo sapiens	95-101
19034039-0	2008	Papaverine, a vasodilator, blocks the pore of the HERG channel at submicromolar concentration.	Papaverine	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	50-54
19056933-5	2009	Intrastriatal infusion of the selective PDE10A inhibitors papaverine or TP-10 [2-{4-[-pyridin-4-yl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]-phenoxymethyl}-quinoline succinic acid] by reverse microdialysis did not affect spontaneous firing but robustly increased measures of cortically evoked spike activity in a stimulus intensity-dependent manner.	Papaverine	58-68	phosphodiesterase 10A	Rattus norvegicus	40-46
19034039-2	2008	To examine the mechanism for this effect, we herein tested the effects of papaverine on human ether-a-go-go (HERG) K channels expressed in HEK293 cells and Xenopus oocytes.	Papaverine	74-84	potassium voltage-gated channel subfamily H member 2	Homo sapiens	109-113
19034039-3	2008	Our results revealed that papaverine dose-dependently decreased the tail currents of HERG channel expressed in HEK293 cells with the IC50 and the Hill coefficient of 0.58 microM and 0.58, respectively, at +20 mV and 36 degrees C. The IC50 for the papaverine-induced blockade of HERG current in Xenopus oocytes was found to decrease progressively relative to depolarization (38.8, 30.0, and 24.8 microM at -10, +20, and +40 mV, respectively).	Papaverine	26-36	potassium voltage-gated channel subfamily H member 2	Homo sapiens	85-89
19034039-3	2008	Our results revealed that papaverine dose-dependently decreased the tail currents of HERG channel expressed in HEK293 cells with the IC50 and the Hill coefficient of 0.58 microM and 0.58, respectively, at +20 mV and 36 degrees C. The IC50 for the papaverine-induced blockade of HERG current in Xenopus oocytes was found to decrease progressively relative to depolarization (38.8, 30.0, and 24.8 microM at -10, +20, and +40 mV, respectively).	Papaverine	26-36	potassium voltage-gated channel subfamily H member 2	Homo sapiens	278-282
19034039-3	2008	Our results revealed that papaverine dose-dependently decreased the tail currents of HERG channel expressed in HEK293 cells with the IC50 and the Hill coefficient of 0.58 microM and 0.58, respectively, at +20 mV and 36 degrees C. The IC50 for the papaverine-induced blockade of HERG current in Xenopus oocytes was found to decrease progressively relative to depolarization (38.8, 30.0, and 24.8 microM at -10, +20, and +40 mV, respectively).	Papaverine	247-257	potassium voltage-gated channel subfamily H member 2	Homo sapiens	85-89
19034039-4	2008	The papaverine-induced blockade of HERG current was time-dependent; the fractional current was 0.92 +/- 0.03 of the control at the beginning of the pulse, but it declined to 0.18 +/- 0.06 after 6 seconds at a test potential of 0 mV.	Papaverine	4-14	potassium voltage-gated channel subfamily H member 2	Homo sapiens	35-39
19034039-5	2008	These results collectively indicate that papaverine blocks HERG channel in a concentration-, voltage-, and time-dependent manner.	Papaverine	41-51	potassium voltage-gated channel subfamily H member 2	Homo sapiens	59-63
19034039-6	2008	Two S6 domain mutations, Y652A and F656A, partially attenuated (Y652A) or abolished (F656A) the hERG current blockade, suggesting that papaverine blocks HERG channel at the pore of the channel.	Papaverine	135-145	ETS transcription factor ERG	Homo sapiens	96-100
19034039-6	2008	Two S6 domain mutations, Y652A and F656A, partially attenuated (Y652A) or abolished (F656A) the hERG current blockade, suggesting that papaverine blocks HERG channel at the pore of the channel.	Papaverine	135-145	potassium voltage-gated channel subfamily H member 2	Homo sapiens	153-157
19034039-8	2008	Therefore, ventricular arrhythmias induced by papaverine could be resulted from the blockage of the HERG channel at the cardiac myocytes.	Papaverine	46-56	potassium voltage-gated channel subfamily H member 2	Homo sapiens	100-104
19133826-6	2008	We identified three drug enhancers of migration, two of which, Papaverine and Isoliquiritigenin, specifically enhance the kit(ts) migration defect, while 8-DPAT affected both melanocyte migration and survival.	Papaverine	63-73	KIT proto-oncogene, receptor tyrosine kinase a	Danio rerio	122-125
18923023-8	2008	In contrast, the PDE10A inhibitor, papaverine, had no effect on TH phosphorylation or dopamine turnover, but instead robustly increased DARPP-32 Thr34 and GluR1 Ser845 phosphorylation in striatal neurons.	Papaverine	35-45	phosphodiesterase 10A	Mus musculus	17-23
18923023-8	2008	In contrast, the PDE10A inhibitor, papaverine, had no effect on TH phosphorylation or dopamine turnover, but instead robustly increased DARPP-32 Thr34 and GluR1 Ser845 phosphorylation in striatal neurons.	Papaverine	35-45	protein phosphatase 1, regulatory inhibitor subunit 1B	Mus musculus	136-144
18923023-8	2008	In contrast, the PDE10A inhibitor, papaverine, had no effect on TH phosphorylation or dopamine turnover, but instead robustly increased DARPP-32 Thr34 and GluR1 Ser845 phosphorylation in striatal neurons.	Papaverine	35-45	glutamate receptor, ionotropic, AMPA1 (alpha 1)	Mus musculus	155-160
18923023-9	2008	Inhibition of PDE10A by papaverine activated cAMP/PKA signaling in both striatonigral and striatopallidal neurons, resulting in potentiation of dopamine D(1) receptor signaling and inhibition of dopamine D(2) receptor signaling.	Papaverine	24-34	phosphodiesterase 10A	Mus musculus	14-20
18923023-9	2008	Inhibition of PDE10A by papaverine activated cAMP/PKA signaling in both striatonigral and striatopallidal neurons, resulting in potentiation of dopamine D(1) receptor signaling and inhibition of dopamine D(2) receptor signaling.	Papaverine	24-34	dopamine receptor D1	Mus musculus	144-166
18923023-9	2008	Inhibition of PDE10A by papaverine activated cAMP/PKA signaling in both striatonigral and striatopallidal neurons, resulting in potentiation of dopamine D(1) receptor signaling and inhibition of dopamine D(2) receptor signaling.	Papaverine	24-34	dopamine receptor D2	Mus musculus	195-217
17899889-8	2007	The direct determination of PA in some formulations (Vasorin injection) gave results that compare favorably with those obtained using the British Pharmacopoeia method.	Papaverine	28-30	vasorin	Homo sapiens	53-60
17913473-3	2008	To test whether the loss of PDE10A activity in the striatum was detrimental to normal brain function, we treated wild-type (WT) mice with chronic administration of papaverine, which is a specific inhibitor of PDE10A.	Papaverine	164-174	phosphodiesterase 10A	Mus musculus	209-215
17913473-14	2008	While papaverine treatment reduced CREB protein levels in the hippocampus and striatum, fluoxetine increased CREB in the hippocampus.	Papaverine	6-16	cAMP responsive element binding protein 1	Mus musculus	35-39
17913473-15	2008	These data suggest that papaverine and fluoxetine may produce quite different effects on behavior; these behaviors may be linked to CREB expression in brain regions associated with motor and cognitive functions.	Papaverine	24-34	cAMP responsive element binding protein 1	Mus musculus	132-136
17913473-16	2008	PDE10A protein levels were decreased by both papaverine and fluoxetine.	Papaverine	45-55	phosphodiesterase 10A	Mus musculus	0-6
18287214-3	2008	Our current understanding of the physiological role of PDE10A and the therapeutic utility of PDE10A inhibitors derives in part from studies with papaverine, the only pharmacological tool for this target extensively profiled to date.	Papaverine	145-155	phosphodiesterase 10A	Homo sapiens	55-61
18287214-3	2008	Our current understanding of the physiological role of PDE10A and the therapeutic utility of PDE10A inhibitors derives in part from studies with papaverine, the only pharmacological tool for this target extensively profiled to date.	Papaverine	145-155	phosphodiesterase 10A	Homo sapiens	93-99
17535590-8	2007	RESULTS: Papaverine of 100 microM into bath solution increased the amplitude of the outward K(+) current which was completely blocked by BKCa blocker, IBX (iberiotoxin) and a calcium chelator, BAPTA (1,2-bis(o-aminophenoxy) ethane-N,N,N",N"-tetraacetic acid) in whole cell mode.	Papaverine	9-19	potassium calcium-activated channel subfamily M alpha 1	Rattus norvegicus	137-141
17376289-0	2007	Inhibitory effects of coronary vasodilator papaverine on heterologously-expressed HERG currents in Xenopus oocytes.	Papaverine	43-53	potassium voltage-gated channel subfamily H member 2	Homo sapiens	82-86
17499224-1	2007	We have purified and investigated the role of adenosine ecto-deaminase (ecto-ADA) in porcine brain synaptic membranes and found a low activity of ecto-ADA in synaptic preparations from the cerebral cortex, hippocampus, striatum and medulla oblongata in the presence of purine transport inhibitors (NBTI, dipyridamole and papaverine).	Papaverine	321-331	adenosine deaminase	Homo sapiens	151-154
17253962-5	2007	We also demonstrate that hT2R14 is a receptor for aristolochic acid and report the first characterization of the ligand specificities of hT2R7, which is a broadly tuned receptor responding to strychnine, quinacrine, chloroquine and papaverine.	Papaverine	232-242	taste 2 receptor member 14	Homo sapiens	25-31
17253962-5	2007	We also demonstrate that hT2R14 is a receptor for aristolochic acid and report the first characterization of the ligand specificities of hT2R7, which is a broadly tuned receptor responding to strychnine, quinacrine, chloroquine and papaverine.	Papaverine	232-242	taste 2 receptor member 7	Homo sapiens	137-142
17376289-1	2007	AIM: To characterize the effects of papaverine on HERG channels expressed in Xenopus oocytes as well as cardiac action potential in rabbit ventricular myocytes.	Papaverine	36-46	potassium voltage-gated channel subfamily H member 2	Homo sapiens	50-54
17376289-6	2007	The blockade of papaverine on HERG currents was not voltage-dependent.	Papaverine	16-26	potassium voltage-gated channel subfamily H member 2	Homo sapiens	30-34
17376289-7	2007	The slope conductance measured as a slope of the fully activated HERG current-voltage curves decreased from 78.03+/-4.25 muS of the control to 56.84+/-5.33, 36.06+/-6.53, and 27.09+/-5.50 microS (n=4) by 30, 100, and 300 micromol/L of papaverine, respectively.	Papaverine	235-245	potassium voltage-gated channel subfamily H member 2	Homo sapiens	65-69
17376289-9	2007	Papaverine blocked HERG channels in the closed, open, and inactivated states.	Papaverine	0-10	potassium voltage-gated channel subfamily H member 2	Homo sapiens	19-23
17376289-10	2007	CONCLUSION: These results showed that papaverine blocked HERG channels in a voltage- and state-independent manner, which may most likely be the major mechanism of papaverine-induced cardiac arrhythmia reported in humans.	Papaverine	38-48	potassium voltage-gated channel subfamily H member 2	Homo sapiens	57-61
17376289-10	2007	CONCLUSION: These results showed that papaverine blocked HERG channels in a voltage- and state-independent manner, which may most likely be the major mechanism of papaverine-induced cardiac arrhythmia reported in humans.	Papaverine	163-173	potassium voltage-gated channel subfamily H member 2	Homo sapiens	57-61
16780899-2	2006	We report that papaverine is a potent, specific inhibitor of PDE10A and use this compound to explore the role of PDE10A in regulating striatal function.	Papaverine	15-25	phosphodiesterase 10A	Rattus norvegicus	61-67
16529753-6	2007	pD(2) values in response to papaverine were higher in apoE(-/-) X than in the other groups.	Papaverine	28-38	apolipoprotein E	Mus musculus	54-58
22436754-7	2006	Papaverine was used in group SPa.	Papaverine	0-10	surfactant protein A2	Homo sapiens	29-32
17228859-1	2007	A papaverine based pharmacophore model for PDE10A inhibition was generated via SBDD and used to design a library of 4-amino-6,7-dimethoxyquinazolines.	Papaverine	2-12	phosphodiesterase 10A	Homo sapiens	43-49
16780899-7	2006	The effects of papaverine on striatal cGMP and CREB and ERK phosphorylation, as well as on conditioned avoidance responding, were absent in PDE10A knockout mice, indicating that the effects of the compound are the result of PDE10A inhibition.	Papaverine	15-25	cAMP responsive element binding protein 1	Mus musculus	47-51
16780899-7	2006	The effects of papaverine on striatal cGMP and CREB and ERK phosphorylation, as well as on conditioned avoidance responding, were absent in PDE10A knockout mice, indicating that the effects of the compound are the result of PDE10A inhibition.	Papaverine	15-25	mitogen-activated protein kinase 1	Mus musculus	56-59
16780899-7	2006	The effects of papaverine on striatal cGMP and CREB and ERK phosphorylation, as well as on conditioned avoidance responding, were absent in PDE10A knockout mice, indicating that the effects of the compound are the result of PDE10A inhibition.	Papaverine	15-25	phosphodiesterase 10A	Mus musculus	224-230
16395740-2	2006	The two compounds exhibit markedly different fragmentation pathways and behaviour under multistage mass spectrometry (MSn), with papaverine displaying a wealth of ions in MS2 and noscapine providing a single dominant ion at each stage of MSn prior to MS4.	Papaverine	129-139	MS2	Homo sapiens	171-174
16395740-2	2006	The two compounds exhibit markedly different fragmentation pathways and behaviour under multistage mass spectrometry (MSn), with papaverine displaying a wealth of ions in MS2 and noscapine providing a single dominant ion at each stage of MSn prior to MS4.	Papaverine	129-139	moesin	Homo sapiens	238-241
16395740-2	2006	The two compounds exhibit markedly different fragmentation pathways and behaviour under multistage mass spectrometry (MSn), with papaverine displaying a wealth of ions in MS2 and noscapine providing a single dominant ion at each stage of MSn prior to MS4.	Papaverine	129-139	MS4	Homo sapiens	251-254
15248981-0	2004	Raman, SERS and theoretical studies of papaverine hydrochloride and its neutral species.	Papaverine	39-63	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	7-11
15787711-8	2005	Moreover, acute treatment with the PDE10A inhibitor papaverine immediately prior to testing attenuated the PCP-induced deficits in extradimensional shift learning across a range of doses.	Papaverine	52-62	phosphodiesterase 10A	Rattus norvegicus	35-41
15688406-6	2005	EV1 lytically infected all 8 human ovarian cancer cell lines tested (2008, DOV13, JAM, OVCA-429, OVCAR-3, OVHS-1, OAW-42 and IGROV-1) but not the immortalized normal ovarian surface epithelial cell line (HOSE) or human PBMCs.	Papaverine	0-3	F11 receptor	Homo sapiens	82-85
16280068-11	2005	Papaverine abolished the vasoconstrictor response to ET-1 and the pulmonary vascular pressures remained close to baseline throughout the experiments.	Papaverine	0-10	endothelin 1	Rattus norvegicus	53-57
15248981-3	2004	The pH dependent Raman and SERS spectra of papaverine hydrochloride were recorded and discussed with the assistance of our theoretical results (harmonical vibrational wavenumbers, Raman scattering activities, total electron density and Natural Population Analysis of the molecule) and the SERS surface selection rules.	Papaverine	43-67	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	27-31
15248981-3	2004	The pH dependent Raman and SERS spectra of papaverine hydrochloride were recorded and discussed with the assistance of our theoretical results (harmonical vibrational wavenumbers, Raman scattering activities, total electron density and Natural Population Analysis of the molecule) and the SERS surface selection rules.	Papaverine	43-67	seryl-tRNA synthetase 2, mitochondrial	Homo sapiens	289-293
14990132-9	2004	Icariin and sildenafil did not influence the MBp (P > 0.05), however, papaverine significant influenced MBp (P < 0.01).	Papaverine	73-83	myelin basic protein	Rattus norvegicus	107-110
15230338-0	2004	Papaverine, an opium alkaloid influences hepatic and pulmonary glutathione S-transferase activity and glutathione content in rats.	Papaverine	0-10	hematopoietic prostaglandin D synthase	Rattus norvegicus	63-88
15230338-1	2004	The present study evaluates the effect of oral administration of papaverine at differential dosing regimens (100 mg/kg bw and 200 mg/kg bw) on the hepatic and pulmonary glutathione S-transferase (GST) activity and glutathione content (GSH) in male Wistar rats.	Papaverine	65-75	hematopoietic prostaglandin D synthase	Rattus norvegicus	169-194
15230338-1	2004	The present study evaluates the effect of oral administration of papaverine at differential dosing regimens (100 mg/kg bw and 200 mg/kg bw) on the hepatic and pulmonary glutathione S-transferase (GST) activity and glutathione content (GSH) in male Wistar rats.	Papaverine	65-75	hematopoietic prostaglandin D synthase	Rattus norvegicus	196-199
15230338-2	2004	Papaverine treatment caused a pronounced increase in GST activity and GSH content at the higher dosing level in the rat liver and lung.	Papaverine	0-10	hematopoietic prostaglandin D synthase	Rattus norvegicus	53-56
15185539-7	2004	Paroxetine, papaverine, and possibly also buspirone interact with cytochrome P450 CYP2D6.	Papaverine	12-22	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	82-88
12168349-18	2002	A significant correlation was recorded between CBF and NADH redox state during changes in blood pressure, papaverine injection, spontaneous drop in blood supply to the brain or during releasing of high ICP levels.	Papaverine	106-116	CCAAT enhancer binding protein zeta	Homo sapiens	47-50
12646997-5	2003	RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities.	Papaverine	21-31	phosphodiesterase 5A	Homo sapiens	76-80
12646997-5	2003	RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities.	Papaverine	21-31	phosphodiesterase 4A	Homo sapiens	85-89
12646997-6	2003	The IC(50) of Icariin and papaverine on PDE5 were 0.432 micromol/L and 0.680 micromol/L, respectively and those on PDE4, 73.50 micromol/L and 3.07 micromol/L, respectively.	Papaverine	26-36	phosphodiesterase 5A	Homo sapiens	40-44
12538825-0	2003	Papaverine blocks hKv1.5 channel current and human atrial ultrarapid delayed rectifier K+ currents.	Papaverine	0-10	potassium voltage-gated channel subfamily A member 5	Homo sapiens	18-24
12538825-3	2003	Using the whole cell configuration of the patch-clamp technique, we found that papaverine inhibited hKv1.5 current in a time- and voltage-dependent manner with an IC(50) value of 43.4 microM at +60 mV.	Papaverine	79-89	potassium voltage-gated channel subfamily A member 5	Homo sapiens	100-106
12538825-6	2003	These results indicate that papaverine blocks hKv1.5 channels and native hKv1.5 channels in a concentration-, voltage-, state-, and time-dependent manner.	Papaverine	28-38	potassium voltage-gated channel subfamily A member 5	Homo sapiens	46-52
12538825-6	2003	These results indicate that papaverine blocks hKv1.5 channels and native hKv1.5 channels in a concentration-, voltage-, state-, and time-dependent manner.	Papaverine	28-38	potassium voltage-gated channel subfamily A member 5	Homo sapiens	73-79
12488800-0	2002	MMP-9 and EBA immunoreactivity after papaverine mediated opening of the blood-brain barrier.	Papaverine	37-47	matrix metallopeptidase 9	Rattus norvegicus	0-5
12646997-7	2003	The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively.	Papaverine	44-54	phosphodiesterase 5A	Homo sapiens	58-62
12646997-7	2003	The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively.	Papaverine	44-54	phosphodiesterase 4A	Homo sapiens	64-68
12646997-7	2003	The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively.	Papaverine	44-54	phosphodiesterase 5A	Homo sapiens	69-83
11929681-1	2002	A simple, accurate and highly sensitive spectrophotometric method is proposed for the rapid determination of meclozine and papaverine hydrochlorides using chromotrope 2B (C2B) and chromotrope 2R (C2R).	Papaverine	123-148	secretoglobin family 2B member 3, pseudogene	Homo sapiens	171-174
11929681-3	2002	The ion-associates exhibit absorption maxima at 536 and 524 nm for C2B and C2R with meclozine HCl and at 540 and 528 nm with papaverine HCl, respectively.	Papaverine	125-139	secretoglobin family 2B member 3, pseudogene	Homo sapiens	67-70
11904450-4	2002	Both electrical stimulation of the cavernous nerve and direct intracavernosal injection of the vasorelaxant drug papaverine cause rapid increases in phosphorylated (activated) Akt and eNOS.	Papaverine	113-123	thymoma viral proto-oncogene 1	Mus musculus	176-179
11904450-4	2002	Both electrical stimulation of the cavernous nerve and direct intracavernosal injection of the vasorelaxant drug papaverine cause rapid increases in phosphorylated (activated) Akt and eNOS.	Papaverine	113-123	nitric oxide synthase 3, endothelial cell	Mus musculus	184-188
11904450-7	2002	Penile erection elicited by papaverine is reduced profoundly in mice with targeted deletion of eNOS.	Papaverine	28-38	nitric oxide synthase 3, endothelial cell	Mus musculus	95-99
11065216-0	2000	Restoration of flow-dependent coronary dilation by ACE inhibition improves papaverine-induced maximal coronary blood flow in hypertensive patients: demonstration that large epicardial coronary arteries are more than conductance vessels.	Papaverine	75-85	angiotensin I converting enzyme	Homo sapiens	51-54
10961741-3	1999	In the same way, the modification of these effects in the presence of an inhibitor of protein kinase (PKA) (Rp-cAMPS), an inhibitor of phosphodiesterase (papaverine) and beta-adrenoreceptor blocking agents (propranolol and atenolol) was studied.	Papaverine	154-164	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	102-105
11200484-0	2000	[Role of xanthine oxidase and xanthine dehydrogenase systems in thymocyte apoptosis, induced by papaverine].	Papaverine	96-106	xanthine dehydrogenase	Homo sapiens	30-52
11200484-3	2000	In papaverine-induced process of thymocyte apoptosis the total activity of xanthine oxidase in thymocytes strongly elevated long before their death, the conversion of xanthine dehydrogenase (D-form) to xanthinoxidase (O-form) and accumulation of O-form in the cultural medium took place.	Papaverine	3-13	xanthine dehydrogenase	Homo sapiens	167-189
11069379-1	2000	OBJECTIVE: To assess the levels of adrenomedullin (a vasodilatory peptide) in penile blood before and after injection with papaverine in impotent men, and in the internal spermatic vein in infertile patients with varicocele, comparing the results with levels in the brachial vein in the same patients.	Papaverine	123-133	adrenomedullin	Homo sapiens	35-49
11069379-5	2000	RESULTS: The mean (SD) intracavernosal adrenomedullin levels in the 14 impotent men were significantly different between the flaccid and papaverine-induced erectile state, at 93.5 (33.0) and 135.8 (34.9) pmol/mL, respectively, (P < 0.05).	Papaverine	137-147	adrenomedullin	Homo sapiens	39-53
11069379-8	2000	CONCLUSION: Injection with papaverine increases adrenomedullin release into penile blood; this release may be responsible for the increase in penile blood flow and penile erection.	Papaverine	27-37	adrenomedullin	Homo sapiens	48-62
10961741-9	1999	Papaverine (3-100 microM) also relaxed the contraction induced by KCl and this effect was significantly displaced to the right with Rp-cAMPS (10 microM) (IC50 12.1 +/- 2.2 vs. 16.5 +/- 3.1 microM).	Papaverine	0-10	calmodulin 2, pseudogene 1	Rattus norvegicus	135-140
10657530-5	1999	TyrOH activation produced by PACAP-27 increased in the presence of the phosphodiesterase inhibitor papaverine indicating the involvement of cAMP.	Papaverine	99-109	tyrosine hydroxylase	Rattus norvegicus	0-5
10909609-8	1998	Of 452 patients, 305 (67.4%) had MRP > 80% after 3 injections of papaverine plus regitine.	Papaverine	68-78	ATP binding cassette subfamily C member 1	Homo sapiens	33-36
10465308-7	1999	In conclusion, the cavernosal expression of PTHrP messenger RNA, the distribution of immunoreactive PTHrP throughout the structuro-functional components of the erectile apparatus and its strong potentiating action on papaverine-induced cavernosal relaxation, collectively suggest that PTHrP participates in the control of cavernosal tone.	Papaverine	217-227	parathyroid hormone-like hormone	Rattus norvegicus	44-49
10465308-7	1999	In conclusion, the cavernosal expression of PTHrP messenger RNA, the distribution of immunoreactive PTHrP throughout the structuro-functional components of the erectile apparatus and its strong potentiating action on papaverine-induced cavernosal relaxation, collectively suggest that PTHrP participates in the control of cavernosal tone.	Papaverine	217-227	parathyroid hormone-like hormone	Rattus norvegicus	100-105
10465308-7	1999	In conclusion, the cavernosal expression of PTHrP messenger RNA, the distribution of immunoreactive PTHrP throughout the structuro-functional components of the erectile apparatus and its strong potentiating action on papaverine-induced cavernosal relaxation, collectively suggest that PTHrP participates in the control of cavernosal tone.	Papaverine	217-227	parathyroid hormone-like hormone	Rattus norvegicus	100-105
9112563-16	1997	Papaverine and prostaglandin E1 suppressed Ang II secretion significantly (p <0.001, p = 0.013).	Papaverine	0-10	angiogenin	Homo sapiens	43-46
9415300-7	1997	At the microvascular level (diameter < 100 microns), however, papaverine induced significant vasodilation in the VEGF-treated animals, and almost no vasodilation in the controls.	Papaverine	65-75	vascular endothelial growth factor A	Rattus norvegicus	116-120
8751623-1	1996	In this study the authors determined the effect of papaverine on regional cerebral blood flow (rCBF) in the angiographically normal arteriolar beds of patients with arteriovenous malformations (AVMs) who underwent transfemoral superselective angiography.	Papaverine	51-61	CCAAT/enhancer binding protein zeta	Rattus norvegicus	95-99
9134983-4	1997	Papaverine and MPP+ were most toxic to TH-positive neurons among the compounds tested.	Papaverine	0-10	tyrosine hydroxylase	Homo sapiens	39-41
9134983-5	1997	The order of the toxicity on TH-positive neurons was papaverine, MPP+, tetrahydropapaverine and then DMPEA.	Papaverine	53-63	tyrosine hydroxylase	Homo sapiens	29-31
9284080-7	1997	Rp-cAMPS antagonized the relaxation elicited by forskolin, papaverine and vinpocetine, but not that of rolipram and 8-BrcAMP.	Papaverine	59-69	calmodulin 2, pseudogene 1	Rattus norvegicus	3-8
8751623-9	1996	In the single-dose study, papaverine increased in rCBF 103%, from 48 +/- 11 to 95 +/- 23 ml/100 g/minute at an MCA pressure of 55 +/- 23 mm Hg.	Papaverine	26-36	CCAAT/enhancer binding protein zeta	Rattus norvegicus	50-54
8751623-11	1996	Papaverine increases rCBF in a direct proportion to baseline MCA pressure, even at low baseline pressures.	Papaverine	0-10	CCAAT/enhancer binding protein zeta	Rattus norvegicus	21-25
8751623-13	1996	In addition, rCBF monitoring may be useful in determining the most effective intraarterial dose of papaverine while minimizing complications due to hyperemia.	Papaverine	99-109	CCAAT/enhancer binding protein zeta	Rattus norvegicus	13-17
7496446-10	1995	These data: (1) consolidate that cAMP is a mediator of penile erection, (2) indicate that papaverine and VIP elicit erection by different mechanisms, (3) suggest that an enhanced penile capacity to generate cAMP in DM may constitute an adaptive response to counteract the previously reported reduction in VIP content and VIP receptors, and (4) indicate that the penile and vascular tissues of the rabbit respond in a similar manner to VIP and papaverine.	Papaverine	90-100	VIP peptides	Oryctolagus cuniculus	305-308
8601816-5	1996	Chronic administration of the phosphodiesterase (PDE) inhibitors rolipram or papaverine also increased expression of CREB mRNA in hippocampus, demonstrating a role for the cAMP cascade.	Papaverine	77-87	cAMP responsive element binding protein 1	Rattus norvegicus	117-121
7496446-10	1995	These data: (1) consolidate that cAMP is a mediator of penile erection, (2) indicate that papaverine and VIP elicit erection by different mechanisms, (3) suggest that an enhanced penile capacity to generate cAMP in DM may constitute an adaptive response to counteract the previously reported reduction in VIP content and VIP receptors, and (4) indicate that the penile and vascular tissues of the rabbit respond in a similar manner to VIP and papaverine.	Papaverine	90-100	VIP peptides	Oryctolagus cuniculus	305-308
7496446-10	1995	These data: (1) consolidate that cAMP is a mediator of penile erection, (2) indicate that papaverine and VIP elicit erection by different mechanisms, (3) suggest that an enhanced penile capacity to generate cAMP in DM may constitute an adaptive response to counteract the previously reported reduction in VIP content and VIP receptors, and (4) indicate that the penile and vascular tissues of the rabbit respond in a similar manner to VIP and papaverine.	Papaverine	90-100	VIP peptides	Oryctolagus cuniculus	305-308
7496446-10	1995	These data: (1) consolidate that cAMP is a mediator of penile erection, (2) indicate that papaverine and VIP elicit erection by different mechanisms, (3) suggest that an enhanced penile capacity to generate cAMP in DM may constitute an adaptive response to counteract the previously reported reduction in VIP content and VIP receptors, and (4) indicate that the penile and vascular tissues of the rabbit respond in a similar manner to VIP and papaverine.	Papaverine	443-453	VIP peptides	Oryctolagus cuniculus	105-108
8309170-11	1993	2.0) for left coronary arteries (LAD, LCX) then for RCA and SVBG and significantly decreased after administration of papaverine.	Papaverine	117-127	tet methylcytosine dioxygenase 1	Homo sapiens	38-41
7889285-9	1994	In the presence of endothelium, bradykinin induced concentration-dependent relaxations with a mean EC50 of 3.2 nM and a maximum response of 95 +/- 1% of papaverine-induced relaxation (control curve).	Papaverine	153-163	kininogen 1	Homo sapiens	32-42
7842397-4	1994	We have studied the effect of a hypotensive dose of atrial natriuretic peptide (n = 16), 8-Br-cGMP (n = 5), and papaverin (n = 7) on plasma ET-1 in anesthetized dogs.	Papaverine	112-121	endothelin 1	Canis lupus familiaris	140-144
8113318-9	1994	In sham occluded rats, SNP (n = 5), SIN 1 (n = 5), and papaverine (n = 5) produced comparable increases in CBF (p > 0.05 from vehicle).	Papaverine	55-65	CCAAT/enhancer binding protein zeta	Rattus norvegicus	107-110
7882466-4	1995	After the injection of papaverine in the midportion of the left anterior descending coronary artery (LAD), the diameter of the proximal LAD (LAD1) was measured by quantitative angiography, whereas that of the proximal circumflex artery (LCx) served as control segment.	Papaverine	23-33	ladinin 1	Homo sapiens	101-104
7882466-4	1995	After the injection of papaverine in the midportion of the left anterior descending coronary artery (LAD), the diameter of the proximal LAD (LAD1) was measured by quantitative angiography, whereas that of the proximal circumflex artery (LCx) served as control segment.	Papaverine	23-33	ladinin 1	Homo sapiens	136-139
7882466-4	1995	After the injection of papaverine in the midportion of the left anterior descending coronary artery (LAD), the diameter of the proximal LAD (LAD1) was measured by quantitative angiography, whereas that of the proximal circumflex artery (LCx) served as control segment.	Papaverine	23-33	ladinin 1	Homo sapiens	141-145
7990719-7	1994	The marked increase of PVR in rat lungs was prevented with papaverine (PVR increased only 58%), suggesting that vasoconstriction was a primary event in rat lungs.	Papaverine	59-69	PVR cell adhesion molecule	Rattus norvegicus	23-26
7990719-7	1994	The marked increase of PVR in rat lungs was prevented with papaverine (PVR increased only 58%), suggesting that vasoconstriction was a primary event in rat lungs.	Papaverine	59-69	PVR cell adhesion molecule	Rattus norvegicus	71-74
7511072-11	1994	Active SOD completely blocked papaverine-induced ascorbyl radical increase, despite preserved flow response (delta ascorbyl = 0.02 +/- 1.6 nmol/L, P = NS); inactivated SOD, catalase, indomethacin, and L-NAME had no effect.	Papaverine	30-40	catalase	Oryctolagus cuniculus	173-181
8443917-12	1993	Furthermore, coronary submaximal vasodilation induced by papaverine (n = 5) and adenosine (n = 5) abolished the beneficial effects of SOD.	Papaverine	57-67	superoxide dismutase 1	Homo sapiens	134-137
8466501-6	1993	At this concentration of ET-1, but not at higher concentrations, the cholestasis was abolished (p > 0.18 vs basal) and the rise in perfusion pressure was decreased (by 62%; p < 0.002) by the vasodilator papaverine.	Papaverine	209-219	endothelin 1	Rattus norvegicus	25-29
8395391-1	1993	In helical strips of dog coronary arteries contracted with prostaglandin F2 alpha, relaxant responses to atrial natriuretic peptide (ANP), nitric oxide (NO), nitroglycerin and 8-bromo cyclic GMP were markedly inhibited or abolished by treatment with a high concentration of sodium nitroprusside, whereas the responses to beraprost and papaverine were not influenced.	Papaverine	335-345	natriuretic peptide A	Canis lupus familiaris	105-131
8467878-2	1993	IL-1 alpha and TNF induced rapid dose-dependent inhibition of stomach motility, with maximal relaxation equal to that induced by 100 microM papaverin, and respective EC50s of 20 and 450 pg/ml.	Papaverine	140-149	interleukin 1 alpha	Rattus norvegicus	0-10
2465934-19	1988	Papaverine, nifedipine and verapamil appear to be less selective than abscisic acid in that they equally inhibit phasic and tonic responses in prostatic vas deferens, but these may be interdependent, yet they more strongly inhibit phasic responses of epididymal vas deferens.	Papaverine	0-10	arginine vasopressin	Rattus norvegicus	153-156
1342232-5	1992	For both purified Hb and whole blood samples, incubation with papaverine, dipyridamole and nifedipine modified P50 (PO2 for half saturation of the Hb/oxygen sites) at pH 7.4: 30.9 mmHg for 0.72 mM papaverine vs 23.9 mmHg for control; 23.9 mmHg for 1.43 mM dipyridamole vs 20.8 mmHg for control; 1.09 mmHg for 2.73 mM nifedipine vs 1.14 mmHg for control stripped Hb.	Papaverine	62-72	nuclear factor kappa B subunit 1	Homo sapiens	111-114
1342232-5	1992	For both purified Hb and whole blood samples, incubation with papaverine, dipyridamole and nifedipine modified P50 (PO2 for half saturation of the Hb/oxygen sites) at pH 7.4: 30.9 mmHg for 0.72 mM papaverine vs 23.9 mmHg for control; 23.9 mmHg for 1.43 mM dipyridamole vs 20.8 mmHg for control; 1.09 mmHg for 2.73 mM nifedipine vs 1.14 mmHg for control stripped Hb.	Papaverine	197-207	nuclear factor kappa B subunit 1	Homo sapiens	111-114
1755833-4	1991	The production of ET-1 was increased by thrombin and decreased by vasodilators such as atrial natriuretic peptide, brain natriuretic peptide and nitroprusside, and by 8-bromo cyclic GMP and papaverine.	Papaverine	190-200	endothelin 1	Homo sapiens	18-22
1714396-4	1991	In the presence of papaverine (1 microM) and IBMX (3 microM), which reduced the 30 nM LTD4-induced contraction to the same extent, the relaxant effect of VIP was not changed, whereas the relaxant effects of isoproterenol and PGE2 were significantly potentiated.	Papaverine	19-29	VIP peptides	Cavia porcellus	154-157
1708708-8	1990	This association was further strengthened when treatment of the Nb2a cells for 24 h with dibutyryl cAMP (1-5 mM), papaverine (5-12.5 micrograms/ml) or 3-isobutyl-1-methylxanthine (IBMX; 50-250 microM) increased the abundance of p32/6.3 1.5- to 3-fold more than serum withdrawal alone.	Papaverine	114-124	transformation related protein 63	Mus musculus	228-235
2153383-8	1990	The cytosolic cAMP-PDE was inhibited by micromolar concentrations of cAMP-PDE inhibitors such as trequinsin, rolipram, dipyridamole or papaverine.	Papaverine	135-145	phosphodiesterase 2A	Bos taurus	19-22
2153383-9	1990	The cGS-PDE was inhibited by micromolar concentrations of trequinsin, dipyridamole and papaverine and was insensitive to rolipram, except for the hydrolysis of cAMP which was inhibited in the micromolar range.	Papaverine	87-97	phosphodiesterase 2A	Bos taurus	4-11
34575827-4	2021	The PDE10A inhibitors PF-2545920, PQ10 and papaverine, the PDE3/4 inhibitor trequinsin and the putative PDE5 inhibitor MY-5445 potently decreased glioblastoma cell proliferation.	Papaverine	43-53	phosphodiesterase 10A	Homo sapiens	4-10
35563045-0	2022	In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines.	Papaverine	20-30	vascular endothelial growth factor A	Homo sapiens	53-87
35563045-3	2022	In this study, the influence of PPV on cell migration (light microscopy), expression of vascular endothelial growth factor (VEGF) B, VEGF R1, VEGF R2, and phosphorylated focal adhesion kinase (pFAK) were investigated using spectrophotometry in MDA-MB-231-, A549- and DU145 cell lines.	Papaverine	32-35	fms related receptor tyrosine kinase 1	Homo sapiens	133-140
35563045-3	2022	In this study, the influence of PPV on cell migration (light microscopy), expression of vascular endothelial growth factor (VEGF) B, VEGF R1, VEGF R2, and phosphorylated focal adhesion kinase (pFAK) were investigated using spectrophotometry in MDA-MB-231-, A549- and DU145 cell lines.	Papaverine	32-35	kinase insert domain receptor	Homo sapiens	142-149
35563045-5	2022	VEGF B expression was reduced to 0.79-, 0.71-, and 0.73-fold after 48 h of exposure to PPV in MDA-MB-231-, A549- and DU145 cells, while PPV exposure of 48 h increased VEGF R1 expression in MDA-MB-231- and DU145 cells to 1.38 and 1.46.	Papaverine	87-90	vascular endothelial growth factor B	Homo sapiens	0-6
35563045-5	2022	VEGF B expression was reduced to 0.79-, 0.71-, and 0.73-fold after 48 h of exposure to PPV in MDA-MB-231-, A549- and DU145 cells, while PPV exposure of 48 h increased VEGF R1 expression in MDA-MB-231- and DU145 cells to 1.38 and 1.46.	Papaverine	87-90	fms related receptor tyrosine kinase 1	Homo sapiens	167-174
35563045-5	2022	VEGF B expression was reduced to 0.79-, 0.71-, and 0.73-fold after 48 h of exposure to PPV in MDA-MB-231-, A549- and DU145 cells, while PPV exposure of 48 h increased VEGF R1 expression in MDA-MB-231- and DU145 cells to 1.38 and 1.46.	Papaverine	136-139	vascular endothelial growth factor B	Homo sapiens	0-6
35563045-5	2022	VEGF B expression was reduced to 0.79-, 0.71-, and 0.73-fold after 48 h of exposure to PPV in MDA-MB-231-, A549- and DU145 cells, while PPV exposure of 48 h increased VEGF R1 expression in MDA-MB-231- and DU145 cells to 1.38 and 1.46.	Papaverine	136-139	fms related receptor tyrosine kinase 1	Homo sapiens	167-174
2812037-3	1989	The EC50 of PTH for renal vasodilatation ranged from 1 to 2 nM for all PTH fragments and maximum vasodilatation ranged from 33 to 41% of the maximum vasodilatation induced by papaverine.	Papaverine	175-185	parathyroid hormone	Rattus norvegicus	12-15
2788970-4	1989	Papaverine given together with FBS has suspended inductive effect of FBS on DNA synthesis and its increasing effect on level of inositol-1,4,5-phosphate.	Papaverine	0-10	fibrosin	Homo sapiens	69-72
3051994-5	1988	In the non-filtering, denervated, papaverine-treated dog kidney, renin release was stimulated by renal arterial infusion of verapamil.	Papaverine	34-44	renin	Canis lupus familiaris	65-70
2840297-1	1988	Cyclic AMP was elevated in rat jejunal mucosa in the presence of adenosine deaminase (2 mg/1) both alone or under conditions of stimulated mucosal cyclic AMP accumulation (forskolin 20 microM/papaverine 100 microM).	Papaverine	192-202	adenosine deaminase	Rattus norvegicus	65-84
8430629-7	1993	Heart rate variations during coronary arteriography were 4 +/- 3 min-1 at baseline and 5 +/- 4 min-1 after papaverine administration.	Papaverine	107-117	CD59 molecule (CD59 blood group)	Homo sapiens	95-100
1362244-5	1992	At a concentration of 100 micrograms/ml, HS-142-1 reversibly prevented ANP-induced relaxation of the isolated rabbit thoracic aorta induced to contract with 3 x 10(-7) M phenylephrine, but not the relaxation induced by sodium nitroprusside, isoproterenol, or papaverine.	Papaverine	259-269	natriuretic peptides A	Oryctolagus cuniculus	71-74
1433545-9	1992	In the patients with prolonged erections to papaverine plus phentolamine the mean duration of a full erectile response to SIN-1 was 57 minutes.	Papaverine	44-54	MAPK associated protein 1	Homo sapiens	122-127
1724288-2	1991	IGF-I-stimulated enzyme activity was inhibited by treatment of oocytes with nonselective phosphodiesterase (PDE) inhibitors, with apparent IC50 values of 2 +/- 1 microM papaverine, 20 +/- 2 microM isobutylmethylxanthine, and 128 +/- 16 microM theophylline.	Papaverine	169-179	insulin like growth factor 1 L homeolog	Xenopus laevis	0-5
2037868-1	1991	Kinetic analysis has shown that isoquinoline, papaverine and berberine act as reversible competitive inhibitors to muscle lactate dehydrogenase and mitochondrial malate dehydrogenase with respect to the coenzyme NADH.	Papaverine	46-56	malic enzyme 2	Homo sapiens	162-182
2037868-2	1991	The inhibitor constants Ki vary from 7.5 microM and 12.6 microM berberine interaction with malate dehydrogenase and lactate dehydrogenase respectively to 91.4 microM and 196.4 microM with papaverine action on these two enzymes.	Papaverine	188-198	malic enzyme 2	Homo sapiens	91-111
2037868-5	1991	A fluorimetric analysis of the binding of the three alkaloids show that the dissociation constants (Kd) for malate dehydrogenase are 2.8 microM (berberine), 46 microM (papaverine) and 86 microM (isoquinoline); the corresponding values for lactate dehydrogenase are 3.1 microM, 52 microM and 114 microM.	Papaverine	168-178	malic enzyme 2	Homo sapiens	108-128
2175599-2	1990	8-Bromo-3",5"-cyclic guanosine monophosphate (cGMP) and papaverine also inhibited ET-1 production.	Papaverine	56-66	endothelin 1	Homo sapiens	82-86
33805209-2	2021	Recently, papaverine was revealed to suppress the HMGB1-RAGE inflammatory signaling pathway and cancer cell proliferation.	Papaverine	10-20	high mobility group box 1	Mus musculus	50-55
33805209-2	2021	Recently, papaverine was revealed to suppress the HMGB1-RAGE inflammatory signaling pathway and cancer cell proliferation.	Papaverine	10-20	advanced glycosylation end product-specific receptor	Mus musculus	56-60
33805209-4	2021	Methods: Papaverine 3D pharmacophore mimetic compounds were selected by the LigandScout software from our in-house, anti-cancer chemical library and assessed for their anti-inflammatory activities by a HMGB1-RAGE-mediated interleukin-6 production assay using macrophage-like RAW264.7 cells.	Papaverine	9-19	high mobility group box 1	Mus musculus	202-207
33805209-4	2021	Methods: Papaverine 3D pharmacophore mimetic compounds were selected by the LigandScout software from our in-house, anti-cancer chemical library and assessed for their anti-inflammatory activities by a HMGB1-RAGE-mediated interleukin-6 production assay using macrophage-like RAW264.7 cells.	Papaverine	9-19	advanced glycosylation end product-specific receptor	Mus musculus	208-212
33805209-4	2021	Methods: Papaverine 3D pharmacophore mimetic compounds were selected by the LigandScout software from our in-house, anti-cancer chemical library and assessed for their anti-inflammatory activities by a HMGB1-RAGE-mediated interleukin-6 production assay using macrophage-like RAW264.7 cells.	Papaverine	9-19	interleukin 6	Mus musculus	222-235
2784141-7	1989	The IL-2 response was prevented using the pulmonary vasodilator, papaverine.	Papaverine	65-75	interleukin-2	Cavia porcellus	4-8
2592779-12	1989	Injecting papaverine before AET significantly reduces MFR, but false positive results do still exist.	Papaverine	10-20	signal regulatory protein alpha	Homo sapiens	54-57
3196389-2	1988	The LPC induced a hitherto not identified metabolic process within the erythrocyte which depended on various factors as the Ca++-concentration, pH-value, and temperature of the suspending medium and which was advanced by guanosine or certain drugs as for instance moxaverine, a derivative of papaverine.	Papaverine	292-302	proprotein convertase subtilisin/kexin type 7	Homo sapiens	4-7
2835134-6	1987	When the arterial pressure rise induced by AII was substantially attenuated or prevented by papaverine administration or blood withdrawal, mean ACTH secretion rates increased 400-800% and mean ACTH concentrations increased by 280-500%.	Papaverine	92-102	proopiomelanocortin	Canis lupus familiaris	144-148
2835134-6	1987	When the arterial pressure rise induced by AII was substantially attenuated or prevented by papaverine administration or blood withdrawal, mean ACTH secretion rates increased 400-800% and mean ACTH concentrations increased by 280-500%.	Papaverine	92-102	proopiomelanocortin	Canis lupus familiaris	193-197
3590114-2	1987	Tumor-induced human platelet aggregation was inhibited by addition of the following agents to platelet-rich plasma (PRP): a calcium channel blocker (verapamil), a chelator of divalent cations (EDTA), stimulators of adenylate cyclase (2-fluoroadenosine and forskolin), and inhibitors of cAMP phosphodiesterase (oxagrelate and papaverine).	Papaverine	325-335	proline rich protein HaeIII subfamily 1	Mus musculus	116-119
6436598-1	1984	The effect of the anti-hypoxic drugs piracetam, nicergoline, papaverine, cinnarizine and aligeron on the activity of bee venom phospholipase A2 was studied in experiments in vitro.	Papaverine	61-71	phospholipase A2 group IB	Homo sapiens	127-143
2424745-3	1986	Forskolin, methylisobutylxanthine, and papaverine all potentiated PTH action.	Papaverine	39-49	parathyroid hormone	Rattus norvegicus	66-69
3839085-5	1985	Treatments with papaverine and AD6 reduced the accumulation of TxB2 and enhanced that of 6KPGF1 alpha occurring after PDI, to different extents, both resulting, however, in reduction of the TxB2/6KPGF1 alpha ratio.	Papaverine	16-26	prolyl 4-hydroxylase subunit beta	Rattus norvegicus	118-121
3812773-2	1987	The thoracic aorta was most sensitive; the apparent concentration of U II producing half-maximal contraction was 6.8 X 10(-10) M. Papaverine, dibutyryl cyclic AMP, forskolin, and nitroprusside antagonized the contractile responses to U II at the apparent concentrations producing 50% inhibition (IC50) of 7.6 X 10(-6), 2.1 X 10(-4), 2.5 X 10(-6), and 1.5 X 10(-8) M, respectively.	Papaverine	130-140	urotensin 2	Rattus norvegicus	69-73
3011441-3	1986	The phosphodiesterase inhibitors isobutyl-methyl-xanthine (IBMX), papaverine and Ro 20-1724 dose dependently inhibited enzyme secretion from FMLP- or A23187-treated cells, and this effect was augmented in the presence of 50-75 microM forskolin.	Papaverine	66-76	formyl peptide receptor 1	Homo sapiens	141-145
2419924-8	1986	Agents which inhibit the transport of adenosine (dipyridamole, dilazep, papaverine) depressed locomotor activity, as did erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, an inhibitor of adenosine deaminase.	Papaverine	72-82	adenosine deaminase	Mus musculus	181-200
2431946-3	1986	Our previous reports have shown that lobuloalveolar development, induced by IPAH, is competitively inhibited by the simultaneous presence of dibutyryl cyclic AMP (Bt2cAMP), prostaglandins (PGs) E1, E2, and B1, and papaverine (pap).	Papaverine	214-224	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	198-208
2431946-3	1986	Our previous reports have shown that lobuloalveolar development, induced by IPAH, is competitively inhibited by the simultaneous presence of dibutyryl cyclic AMP (Bt2cAMP), prostaglandins (PGs) E1, E2, and B1, and papaverine (pap).	Papaverine	214-217	ATPase, H+ transporting, lysosomal V1 subunit E1	Mus musculus	198-208
3872304-9	1985	Mean high CPK in the papaverine group was 163 units and 182 units in the control group.	Papaverine	21-31	phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha	Homo sapiens	10-13
6501444-4	1984	Dipyridamole and papaverine, inhibitors of adenosine uptake, potentiated the increase in CBF during anoxia.	Papaverine	17-27	CCAAT/enhancer binding protein zeta	Rattus norvegicus	89-92
6090838-3	1984	At 70% inhibitory concentration of platelet aggregation (PA) induced by papaverine or theophylline, a small but significant increase in platelet c-AMP level was found.	Papaverine	72-82	cathelicidin antimicrobial peptide	Homo sapiens	145-150
6737290-0	1984	Inhibition by papaverine of calcium movements and tension in the smooth muscles of rat vas deferens and urinary bladder.	Papaverine	14-24	arginine vasopressin	Rattus norvegicus	87-90
6747823-5	1984	Whereas the standard calmodulin antagonist W-7 inhibited both parameters by approximately 50% at 10(-4) M, diazoxide, hydralazine, 3-isobutyl-1-methylxanthine, papaverine, propranolol, nifedipine, nitrendipine, sodium nitroprusside and verapamil did not significantly inhibit either parameter at equimolar concentrations.	Papaverine	160-170	calmodulin 1	Homo sapiens	21-31
6375270-13	1984	Papaverine hydrochloride increased rCBF either transiently or continuously in all cats.	Papaverine	0-24	CCAAT/enhancer binding protein zeta	Rattus norvegicus	35-39
6737290-2	1984	At 150 micron, papaverine caused an 80 and 60% inhibition of phasic tension in vas deferens and urinary bladder muscle respectively.	Papaverine	15-25	arginine vasopressin	Rattus norvegicus	79-82
6737290-6	1984	Papaverine at 150 micron caused a small fall in resting 45Ca efflux from vas deferens and a larger fall in efflux from bladder muscle.	Papaverine	0-10	arginine vasopressin	Rattus norvegicus	73-76
6353937-3	1983	Conversely, renal arterial infusion of verapamil in dogs with nonfiltering, denervated, papaverine-treated kidneys resulted in no change in renal blood flow and a significant increase (P less than 0.05) in renin secretion.	Papaverine	88-98	renin	Canis lupus familiaris	206-211
6316066-3	1983	In the case of all arteries contracted with PGF2 alpha, the ED50 of PTH vasorelaxation related to maximal vasorelaxation induced by papaverine ranged from 9 to 14 nM for bPTH-(1-34) and 100 to 220 ng/ml for native bPTH-(1-84).	Papaverine	132-142	parathyroid hormone	Bos taurus	68-71
6630314-2	1983	papaverine on regional cerebral blood flow (rCBF).	Papaverine	0-10	CCAAT/enhancer binding protein zeta	Rattus norvegicus	44-48
6324652-0	1984	Response of C-6 glioma to isoproterenol and papaverine in vivo depends on beta-adrenergic receptor density.	Papaverine	44-54	complement C6	Rattus norvegicus	12-15
6324652-2	1984	C-6 glioma cells carried to high culture passages in medium containing 10% fetal bovine serum when injected in vivo are unresponsive to treatment with the beta-adrenergic agonist isoproterenol and the phosphodiesterase inhibitor papaverine.	Papaverine	229-239	complement C6	Rattus norvegicus	0-3
6442910-2	1984	Incubation of arterial or venous platelet-rich plasma (PRP) with papaverine, a phosphodiesterase blocker, resulted in a more marked inhibition of the aggregation parameters for arterial than for venous PRP, indicating that a cAMP-dependent mechanism is involved.	Papaverine	65-75	proline rich protein 2-like 1	Rattus norvegicus	55-58
6442910-2	1984	Incubation of arterial or venous platelet-rich plasma (PRP) with papaverine, a phosphodiesterase blocker, resulted in a more marked inhibition of the aggregation parameters for arterial than for venous PRP, indicating that a cAMP-dependent mechanism is involved.	Papaverine	65-75	proline rich protein 2-like 1	Rattus norvegicus	202-205
6318728-7	1983	The interaction of the second calmodulin-binding form with calmodulin is disrupted by the papaverine derivative verapamil without significantly altering the hydrolytic activity of the enzyme.	Papaverine	90-100	calmodulin 2	Gallus gallus	30-40
6318728-7	1983	The interaction of the second calmodulin-binding form with calmodulin is disrupted by the papaverine derivative verapamil without significantly altering the hydrolytic activity of the enzyme.	Papaverine	90-100	calmodulin 2	Gallus gallus	59-69
6336540-1	1983	On isolated rat vas deferens both papaverine and verapamil show a non competitive antagonism against norepinephrine and a competitive antagonism against Ca2+.	Papaverine	34-44	arginine vasopressin	Rattus norvegicus	16-19
6350561-7	1983	In conscious sheep given an infusion of papaverine, furosemide also produced an increase in plasma active renin and a concurrent decrease in the inactive form.	Papaverine	40-50	renin	Ovis aries	106-111
7044151-8	1982	Papaverine treatment, to prevent vascular-GFR changes without blocking alpha-receptors, resulted in similar renin responses.	Papaverine	0-10	renin	Felis catus	108-113
6184146-5	1982	Enterotoxin specific activity was increased for three strains by adding papaverine (hydrochloride crystalline), for two strains by adding each of caffeine and 3-isobutyl-l-methylxanthine, for one strain by adding each of theophylline, 6-mercaptopurine, and 2-amino-6-mercaptopurine, and for none of the strains by adding imidazole.	Papaverine	72-82	cpe	Clostridium perfringens	0-11
7208577-1	1980	Part 6: The stability of aqueous solutions of papaverine hydrochloride (author"s transl)].	Papaverine	46-70	tankyrase 2	Homo sapiens	0-6
6177320-5	1982	However, in the presence of EGTA, papaverine inhibition of cyclic GMP but not cyclic AMP phosphodiesterase was reduced significantly.	Papaverine	34-44	5'-nucleotidase, cytosolic II	Homo sapiens	66-69
6274151-2	1981	It was observed that some drugs which elevate the cAMP level such as papaverine, histamine +K+ and dibutyryl cAMP elevated the electric seizure threshold while in penicillin-induced epilepsy they reduced the occurrence of ictal activity and the interictal spike frequency.	Papaverine	69-79	cathelicidin antimicrobial peptide	Homo sapiens	50-54
6267154-4	1981	Phosphodiesterase inhibitors (3-isobutyl-1--methylxanthine and papaverine) simultaneously stimulated tyrosinase activity and inhibited melanin production, presumably by allowing endogenous cyclic AMP and cyclic GMP to accumulate intracellularly.	Papaverine	63-73	tyrosinase	Homo sapiens	101-111
6267154-4	1981	Phosphodiesterase inhibitors (3-isobutyl-1--methylxanthine and papaverine) simultaneously stimulated tyrosinase activity and inhibited melanin production, presumably by allowing endogenous cyclic AMP and cyclic GMP to accumulate intracellularly.	Papaverine	63-73	5'-nucleotidase, cytosolic II	Homo sapiens	211-214
6256256-4	1981	Papaverine was administered alone and simultaneously with bethanechol or the octapeptide of cholecystokinin.	Papaverine	0-10	cholecystokinin	Homo sapiens	92-107
6256256-8	1981	Papaverine (10(-6) M had a minimal effect on the increase in spike activity that occurred after octapeptide of cholecystokinin in a concentration of 4 x 10(-10) M (p < 0.05).	Papaverine	0-10	cholecystokinin	Homo sapiens	111-126
6256256-10	1981	These studies show that (a) papaverine can inhibit smooth muscle myoelectrical activity, (b) papaverine is a potent inhibitor of cholinergic stimulation of colonic smooth muscle, but (c) papaverine has a minimal effect on octapeptide of cholecystokinin stimulation of the isolated colonic smooth muscle.	Papaverine	93-103	cholecystokinin	Homo sapiens	237-252
6256256-10	1981	These studies show that (a) papaverine can inhibit smooth muscle myoelectrical activity, (b) papaverine is a potent inhibitor of cholinergic stimulation of colonic smooth muscle, but (c) papaverine has a minimal effect on octapeptide of cholecystokinin stimulation of the isolated colonic smooth muscle.	Papaverine	93-103	cholecystokinin	Homo sapiens	237-252
419151-0	1979	The effect of papaverine on in vitro renin secretion.	Papaverine	14-24	renin	Homo sapiens	37-42
7224713-4	1980	The secretory activity of 1 mg of papaverine was approximately equal to that of 0.06 units of secretin.	Papaverine	34-44	SCT	Canis lupus familiaris	94-102
7224713-9	1980	On the other hand, papaverine significantly potentiated the secretion of pancreatic juice induced by secretin.	Papaverine	19-29	SCT	Canis lupus familiaris	101-109
435132-5	1979	When postural hypotension was induced, rCBF became significantly reduced in patients with VBI whether or not they were treated with papaverine.	Papaverine	132-142	CCAAT/enhancer binding protein zeta	Rattus norvegicus	39-43
6993660-5	1980	Relaxation by isoproterenol and papaverine in serotonin-contracted aortas was the same in AHR and normotensive controls 2 and 28 days postoperatively but was reduced at 6 and 14 days.	Papaverine	32-42	aryl hydrocarbon receptor	Rattus norvegicus	90-93
6104991-3	1980	Phosphodiesterase inhibitors, papaverine, 3-isobutyl-1-methylxantine, SQ-20009 increase and prolong the effects of cyclic nucleotides and the complex effect of cyclic GMP is transformed into simple hyperpolarization.	Papaverine	30-40	5'-nucleotidase, cytosolic II	Homo sapiens	167-170
230369-3	1979	Only papaverine and dipyridamole significantly increased the concentration of c-AMP in the coronary artery.	Papaverine	5-15	cathelicidin antimicrobial peptide	Canis lupus familiaris	78-83
230369-6	1979	Group I, including papaverine, dipyridamole, and amyl nitrite, increased the concentration of c-AMP and the ratio of c-AMP to c-GMP.	Papaverine	19-29	cathelicidin antimicrobial peptide	Canis lupus familiaris	94-99
230369-6	1979	Group I, including papaverine, dipyridamole, and amyl nitrite, increased the concentration of c-AMP and the ratio of c-AMP to c-GMP.	Papaverine	19-29	cathelicidin antimicrobial peptide	Canis lupus familiaris	117-122
41090-16	1979	However pre-injection of 10(-2) M-papaverine enhances the response to a subsequent injection of 10(-3) M-cyclic GMP.	Papaverine	34-44	5'-nucleotidase, cytosolic II	Homo sapiens	112-115
401005-3	1979	Papaverine was given in slow-release capsules at 150 mg BID for one week followed by 300 mg BID for five weeks.	Papaverine	0-10	BH3 interacting domain death agonist	Homo sapiens	56-59
205421-3	1978	Papaverine (3 X 10(-5) M) potentiated the effects of temperature on cAMP and force of contraction on left atria driven at 0.5 Hz.	Papaverine	0-10	cathelicidin antimicrobial peptide	Cavia porcellus	68-72
205421-4	1978	On right atria beating spontaneously at frequencies above 2 Hz papaverine only potentiated the effect of decreasing temperatures on the response of cAMP but not on that of force of contraction.	Papaverine	63-73	cathelicidin antimicrobial peptide	Cavia porcellus	148-152
205421-7	1978	As with the time courses for isoprenaline, dose-response curves for the effect of isoprenaline and papaverine on cAMP content and force of contraction also appeared to be shifted towards higher levels at hypothemia.	Papaverine	99-109	cathelicidin antimicrobial peptide	Cavia porcellus	113-117
191099-6	1977	An inhibitor of phosphodiesterases, papaverine, increases and prolongates effects of cyclic 3",5"-AMP and cyclic 3",5"-GMP, but in latter case the action of this drug seems to be less.	Papaverine	36-46	5'-nucleotidase, cytosolic II	Homo sapiens	119-122
204304-0	1978	Inhibition of 15-hydroxyprostaglandin dehydrogenase by papaverine.	Papaverine	55-65	carbonyl reductase 1	Homo sapiens	14-51
194013-6	1977	The correlation between cyclic GMP and permeability or swelling is maintained in the presence of two pharmacological perturbations: papaverine, a phosphodiesterase inhibitor, increases both cyclic GMP levels and the dark permeability of the plasma membrane; and beta,gamma-methylene ATP increases the effectiveness of light in suppressing both permeability and cyclic GMP levels.	Papaverine	132-142	5'-nucleotidase, cytosolic II	Homo sapiens	31-34
194013-6	1977	The correlation between cyclic GMP and permeability or swelling is maintained in the presence of two pharmacological perturbations: papaverine, a phosphodiesterase inhibitor, increases both cyclic GMP levels and the dark permeability of the plasma membrane; and beta,gamma-methylene ATP increases the effectiveness of light in suppressing both permeability and cyclic GMP levels.	Papaverine	132-142	5'-nucleotidase, cytosolic II	Homo sapiens	197-200
194013-6	1977	The correlation between cyclic GMP and permeability or swelling is maintained in the presence of two pharmacological perturbations: papaverine, a phosphodiesterase inhibitor, increases both cyclic GMP levels and the dark permeability of the plasma membrane; and beta,gamma-methylene ATP increases the effectiveness of light in suppressing both permeability and cyclic GMP levels.	Papaverine	132-142	5'-nucleotidase, cytosolic II	Homo sapiens	197-200
755346-0	1978	Effect of papaverine on renin release in dogs in vivo and in vitro.	Papaverine	10-20	renin	Canis lupus familiaris	24-29
755346-4	1978	Renin activity (PRA) of arterial blood and renal venous blood, veno-arterious PRA-difference and renin secretion increased significantly after papaverine infusion.	Papaverine	143-153	renin	Canis lupus familiaris	0-5
755346-4	1978	Renin activity (PRA) of arterial blood and renal venous blood, veno-arterious PRA-difference and renin secretion increased significantly after papaverine infusion.	Papaverine	143-153	renin	Canis lupus familiaris	97-102
755346-6	1978	Papaverine caused a significant increase in renin release and in tissue cAMP concentration.	Papaverine	0-10	renin	Canis lupus familiaris	44-49
609151-2	1977	The differential effect of papaverine and rotenone on DT diaphorase.	Papaverine	27-37	NAD(P)H dehydrogenase [quinone] 1	Cavia porcellus	54-67
840860-0	1977	Renin secretion after papaverine and furosemide in conscious sheep.	Papaverine	22-32	renin	Ovis aries	0-5
970477-3	1976	Renal vasoconstriction induced by infusion of phenylephrine or methoxamine increased PRA, whereas vasodilatation by papaverine suppressed renin activity.	Papaverine	116-126	renin	Rattus norvegicus	138-143
970477-4	1976	The increased renin activity induced by phenylephrine was blocked by high pressure or papaverine.	Papaverine	86-96	renin	Rattus norvegicus	14-19
177385-6	1976	The insulin-induced mitotic response was inhibited by dibutyryl cAMP and theophylline or papaverine or 8-bromoadenosine cAMP.	Papaverine	89-99	insulin	Homo sapiens	4-11
1797-5	1975	Phosphodiesterase inhibitors (aminophylline, caffeine, and papaverine) given alone to the conscious dogs did not initiate pancreatic bicarbonate secretion, but they potentiated bicarbonate responses to exogenous secretin.	Papaverine	59-69	SCT	Canis lupus familiaris	212-220
177073-10	1976	Papaverine and EG 626 acted as competitive inhibitors of each fraction with virtually the same Ki value in both assays using either cyclic AMP or cyclic GMP as the substrate.	Papaverine	0-10	5'-nucleotidase, cytosolic II	Homo sapiens	153-156
177799-2	1976	Acetylcholine, histamine and papaverine increased both cyclic AMP and cyclic GMP levels in the tracheal muscle.	Papaverine	29-39	5'-nucleotidase, cytosolic II	Homo sapiens	77-80
973520-3	1976	THese indices may point to connections between the cerebral circulation and changes in the concentration of H ions in the CSF under the influence of papaverine.	Papaverine	149-159	colony stimulating factor 2	Homo sapiens	122-125
1182938-5	1975	Prior dilation of the nonfiltering kidney with either acetylcholine or papaverine prevented changes in both resistance and renin secretion.	Papaverine	71-81	renin	Canis lupus familiaris	123-128
1203355-4	1975	Caffeine (10(-4) M) and papaverine (10(-7) M) activated GAMT in retina and rat Harderian gland, while cycloheximide, a protein synthesis inhibitor (0.5-2 mkg/ml), eliminated caffeine-stimulated GAMT activity.	Papaverine	24-34	guanidinoacetate N-methyltransferase	Rattus norvegicus	56-60
170158-12	1975	Other modifiers of cAMP which were effective included prostaglandins E1, E2, and F2alpha (2 times 10(-6) M) and papaverine (1 muM).	Papaverine	112-122	antimicrobial protein CAP18	Oryctolagus cuniculus	19-23
1095631-3	1975	Period analysis revealed that a 300-mg dose of papaverine (Pavabid Plateau Caps) increased EEG alpha activity (8-13 cycles per second) and decreased the beta2 range (27-40 cps).	Papaverine	47-57	potassium calcium-activated channel subfamily M regulatory beta subunit 2	Homo sapiens	153-158
239732-17	1975	Rg 1 and Re showed vasodilator action in dogs, the potencies of which were 1/20 and 1/50 of that of papaverine, respectively.	Papaverine	100-110	protein phosphatase 1, regulatory subunit 3A	Mus musculus	0-4
238863-4	1975	The results show a significant increase in tissue cyclic AMP concentration at a time when the muscle was just beginning to relax in response to papaverine, but not in response to chenodesoxycholate.	Papaverine	144-154	neurogenin 3	Rattus norvegicus	123-128
1203355-4	1975	Caffeine (10(-4) M) and papaverine (10(-7) M) activated GAMT in retina and rat Harderian gland, while cycloheximide, a protein synthesis inhibitor (0.5-2 mkg/ml), eliminated caffeine-stimulated GAMT activity.	Papaverine	24-34	guanidinoacetate N-methyltransferase	Rattus norvegicus	194-198
33914237-3	2021	The present study was undertaken to determine the possible neuroprotective effects and the associated mechanism of papaverine (PAP), a PDE10A isoenzyme inhibitor, against quinolinic acid (QUIN)-induced excitotoxicity using human primary cortical neurons.	Papaverine	115-125	phosphodiesterase 10A	Homo sapiens	135-141
33911050-0	2021	Papaverine Exerts Neuroprotective Effect by Inhibiting NLRP3 Inflammasome Activation in an MPTP-Induced Microglial Priming Mouse Model Challenged with LPS.	Papaverine	0-10	NLR family, pyrin domain containing 3	Mus musculus	55-60
33675044-9	2021	Papaverine exposure was associated with higher rate of preterm delivery (22.3% vs. 10.3%, p<0.001), CS (35.9% vs. 24.1%, p<0.001) and lower birth weight (3207 grams vs. 3246 grams, p=0.02).	Papaverine	0-10	citrate synthase	Homo sapiens	100-102
33480092-3	2021	We investigated the role of a selective phosphodiesterase-10A (PDE10A) inhibitor, papaverine on ASD related behavioural phenotypes (social behaviour deficits, repetitive behaviour, anxiety and hyperlocomotion) in developmental hyperserotonemia (DHS) rat model.	Papaverine	82-92	phosphodiesterase 10A	Rattus norvegicus	63-69
33480092-7	2021	Also, papaverine administration significantly increased the levels of BDNF, pCREB/CREB, IL-10, GSH and significantly decreased TNF-alpha, IL-6 and TBARS levels in different brain areas.	Papaverine	6-16	brain-derived neurotrophic factor	Rattus norvegicus	70-74
33480092-7	2021	Also, papaverine administration significantly increased the levels of BDNF, pCREB/CREB, IL-10, GSH and significantly decreased TNF-alpha, IL-6 and TBARS levels in different brain areas.	Papaverine	6-16	cAMP responsive element binding protein 1	Rattus norvegicus	77-81
33480092-7	2021	Also, papaverine administration significantly increased the levels of BDNF, pCREB/CREB, IL-10, GSH and significantly decreased TNF-alpha, IL-6 and TBARS levels in different brain areas.	Papaverine	6-16	interleukin 10	Rattus norvegicus	88-93
33480092-7	2021	Also, papaverine administration significantly increased the levels of BDNF, pCREB/CREB, IL-10, GSH and significantly decreased TNF-alpha, IL-6 and TBARS levels in different brain areas.	Papaverine	6-16	tumor necrosis factor	Rattus norvegicus	127-136
33480092-7	2021	Also, papaverine administration significantly increased the levels of BDNF, pCREB/CREB, IL-10, GSH and significantly decreased TNF-alpha, IL-6 and TBARS levels in different brain areas.	Papaverine	6-16	interleukin 6	Rattus norvegicus	138-142
33389727-6	2021	Molecular docking and molecular dynamics simulation of Papaverine against the target Bcr-Abl were also carried out.	Papaverine	55-65	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	85-92
33389727-9	2021	Papaverine induces ROS generation, promotes apoptosis, and inhibits Bcr-Abl downstream signaling.	Papaverine	0-10	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	68-75
33389727-11	2021	Furthermore, the docking and molecular dynamic simulation studies supported that Papaverine binds to the allosteric site of Bcr-Abl.	Papaverine	81-91	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	124-131
33476858-0	2021	Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-<kappa>B pathway.	Papaverine	0-10	advanced glycosylation end product-specific receptor	Mus musculus	117-121
33476858-0	2021	Papaverine provides neuroprotection by suppressing neuroinflammation and apoptosis in the traumatic brain injury via RAGE- NF-<kappa>B pathway.	Papaverine	0-10	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	123-134
33476858-2	2021	The aim of the study is to investigate effects of papaverine on secondary signaling mechanisms through this pathway in mice TBI model.Immunohistochemically, while the number of RAGE and NF- kappaB positive cells, apoptotic cells increased, the number of NeuN positive cells reduced in TBI.Papaverine reduced the number of RAGE positive cells on glia and the number of NF- kappaB positive cells on both neuron and glia.	Papaverine	50-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	186-196
33476858-2	2021	The aim of the study is to investigate effects of papaverine on secondary signaling mechanisms through this pathway in mice TBI model.Immunohistochemically, while the number of RAGE and NF- kappaB positive cells, apoptotic cells increased, the number of NeuN positive cells reduced in TBI.Papaverine reduced the number of RAGE positive cells on glia and the number of NF- kappaB positive cells on both neuron and glia.	Papaverine	50-60	RNA binding protein, fox-1 homolog (C. elegans) 3	Mus musculus	254-258
33476858-2	2021	The aim of the study is to investigate effects of papaverine on secondary signaling mechanisms through this pathway in mice TBI model.Immunohistochemically, while the number of RAGE and NF- kappaB positive cells, apoptotic cells increased, the number of NeuN positive cells reduced in TBI.Papaverine reduced the number of RAGE positive cells on glia and the number of NF- kappaB positive cells on both neuron and glia.	Papaverine	50-60	advanced glycosylation end product-specific receptor	Mus musculus	322-326
33476858-2	2021	The aim of the study is to investigate effects of papaverine on secondary signaling mechanisms through this pathway in mice TBI model.Immunohistochemically, while the number of RAGE and NF- kappaB positive cells, apoptotic cells increased, the number of NeuN positive cells reduced in TBI.Papaverine reduced the number of RAGE positive cells on glia and the number of NF- kappaB positive cells on both neuron and glia.	Papaverine	50-60	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	368-378
33476858-5	2021	Results of this study showed that papaverine reduced TBI- induced neuroinflammation and apoptosis, also provided neuroprotection via the RAGE- NF-kappaB signal path, which is one of the possible mechanisms in TBI.	Papaverine	34-44	advanced glycosylation end product-specific receptor	Mus musculus	137-141
33476858-5	2021	Results of this study showed that papaverine reduced TBI- induced neuroinflammation and apoptosis, also provided neuroprotection via the RAGE- NF-kappaB signal path, which is one of the possible mechanisms in TBI.	Papaverine	34-44	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	143-152
33175424-7	2021	Also, papaverine resulted in significant increase of the levels in BDNF, pCREB, IL-10 and GSH along with significant decrease of TNF-alpha, IL-6 and TBARS in different brain areas of PAE group.	Papaverine	6-16	brain derived neurotrophic factor	Homo sapiens	67-71
33360527-0	2021	Biotransformation of papaverine and in silico docking studies of the metabolites on human phosphodiesterase 10a.	Papaverine	21-31	phosphodiesterase 10A	Homo sapiens	90-111
33360527-5	2021	In silico docking studies of the metabolites using crystals of human phosphodiesterase 10a (hPDE10a) revealed that compounds 4, 1, 6, 3, and 5 possess better docking scores and binding poses with favorable interactions than the native ligand papaverine.	Papaverine	242-252	phosphodiesterase 10A	Homo sapiens	92-99
32979223-0	2021	Antinociceptive activity of the novel RAGE inhibitor, papaverine, in a mouse model of chronic inflammatory pain.	Papaverine	54-64	advanced glycosylation end product-specific receptor	Mus musculus	38-42
32979223-2	2021	The aim of the present study was to investigate whether papaverine, a novel RAGE inhibitor, could suppress inflammatory pain in mice after several time points, which was induced by the injection of complete Freund"s adjuvant (CFA).	Papaverine	56-66	advanced glycosylation end product-specific receptor	Mus musculus	76-80
33175424-7	2021	Also, papaverine resulted in significant increase of the levels in BDNF, pCREB, IL-10 and GSH along with significant decrease of TNF-alpha, IL-6 and TBARS in different brain areas of PAE group.	Papaverine	6-16	interleukin 10	Homo sapiens	80-85
33175424-7	2021	Also, papaverine resulted in significant increase of the levels in BDNF, pCREB, IL-10 and GSH along with significant decrease of TNF-alpha, IL-6 and TBARS in different brain areas of PAE group.	Papaverine	6-16	tumor necrosis factor	Homo sapiens	129-138
33175424-7	2021	Also, papaverine resulted in significant increase of the levels in BDNF, pCREB, IL-10 and GSH along with significant decrease of TNF-alpha, IL-6 and TBARS in different brain areas of PAE group.	Papaverine	6-16	interleukin 6	Homo sapiens	140-144
33175424-8	2021	Papaverine, a selective PDE10A inhibitor rectified behavioural phenotypes associated with ADHD, possibly by altering protein markers associated with neuronal survival, neuronal transcription factor, brain inflammation, and brain oxidative stress.	Papaverine	0-10	phosphodiesterase 10A	Homo sapiens	24-30
33041002-1	2020	We previously identified papaverine as an inhibitor of receptor for advanced glycation end-products (RAGE) and showed its suppressive effect on high mobility group box 1 (HMGB1)-mediated responses to inflammation.	Papaverine	25-35	advanced glycosylation end product-specific receptor	Mus musculus	55-99
33127361-7	2021	Also, papaverine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB, IL-10 and GSH along with significant decrease in TNF-alpha, IL-6 and TBARS in different brain areas of Pre-VPA group.	Papaverine	6-16	brain-derived neurotrophic factor	Rattus norvegicus	69-73
33127361-7	2021	Also, papaverine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB, IL-10 and GSH along with significant decrease in TNF-alpha, IL-6 and TBARS in different brain areas of Pre-VPA group.	Papaverine	6-16	doublecortin	Rattus norvegicus	89-92
33127361-7	2021	Also, papaverine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB, IL-10 and GSH along with significant decrease in TNF-alpha, IL-6 and TBARS in different brain areas of Pre-VPA group.	Papaverine	6-16	interleukin 10	Rattus norvegicus	101-106
33127361-7	2021	Also, papaverine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB, IL-10 and GSH along with significant decrease in TNF-alpha, IL-6 and TBARS in different brain areas of Pre-VPA group.	Papaverine	6-16	tumor necrosis factor	Rattus norvegicus	150-159
33127361-7	2021	Also, papaverine resulted in a significant increase in the levels of BDNF, synapsin-IIa, DCX, pCREB, IL-10 and GSH along with significant decrease in TNF-alpha, IL-6 and TBARS in different brain areas of Pre-VPA group.	Papaverine	6-16	interleukin 6	Rattus norvegicus	161-165
33461822-8	2021	RESULTS: Patients receiving papaverine perfusion via the aortic root before heart re-beating during heart valve replacement surgery under CPB showed less extracorporeal circulation time and CPB time, higher automatic heartbeat recovery rate, less mechanical ventilation time, shorter ICU and in-hospital stay, less leak of cTnI and CK-MB, and weaker inflammatory response than the patients in control group.	Papaverine	28-38	troponin I3, cardiac type	Homo sapiens	323-327
33461822-9	2021	In addition, the protein expression of IL-6/8/10 and TNF-alpha was reduced by the perfusion of papaverine.	Papaverine	95-105	interleukin 6	Homo sapiens	39-48
33461822-9	2021	In addition, the protein expression of IL-6/8/10 and TNF-alpha was reduced by the perfusion of papaverine.	Papaverine	95-105	tumor necrosis factor	Homo sapiens	53-62
33461822-11	2021	CONCLUSION: Papaverine perfusion presented positive effect during valve replacement; this cardioprotective effect may be associated with inhibition of inflammatory response and NF-kappaB.	Papaverine	12-22	nuclear factor kappa B subunit 1	Homo sapiens	177-186
33041002-1	2020	We previously identified papaverine as an inhibitor of receptor for advanced glycation end-products (RAGE) and showed its suppressive effect on high mobility group box 1 (HMGB1)-mediated responses to inflammation.	Papaverine	25-35	advanced glycosylation end product-specific receptor	Mus musculus	101-105
33041002-1	2020	We previously identified papaverine as an inhibitor of receptor for advanced glycation end-products (RAGE) and showed its suppressive effect on high mobility group box 1 (HMGB1)-mediated responses to inflammation.	Papaverine	25-35	high mobility group box 1	Mus musculus	144-169
33041002-1	2020	We previously identified papaverine as an inhibitor of receptor for advanced glycation end-products (RAGE) and showed its suppressive effect on high mobility group box 1 (HMGB1)-mediated responses to inflammation.	Papaverine	25-35	high mobility group box 1	Mus musculus	171-176
33041002-3	2020	Trimebutine was revealed to have more potent suppressive effects on HMGB1-induced production of pro-inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha in macrophage-like RAW264.7 cells and mouse bone marrow primarily differentiated macrophages than did papaverine.	Papaverine	280-290	high mobility group box 1	Mus musculus	68-73
32842806-0	2020	Papaverine Has Therapeutic Potential for Sepsis-Induced Neuropathy in Rats, Possibly via the Modulation of HMGB1-RAGE Axis and Its Antioxidant Prosperities.	Papaverine	0-10	high mobility group box 1	Rattus norvegicus	107-112
32768884-0	2020	Papaverine inhibits alpha-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson"s disease.	Papaverine	0-10	synuclein, alpha	Mus musculus	20-35
32768884-0	2020	Papaverine inhibits alpha-synuclein aggregation by modulating neuroinflammation and matrix metalloproteinase-3 expression in the subacute MPTP/P mouse model of Parkinson"s disease.	Papaverine	0-10	matrix metallopeptidase 3	Mus musculus	84-110
32842806-11	2020	Considering its anti-inflammatory and antioxidant properties, papaverine"s neuroprotective effects possibly stem from the suppression of the RAGE-HMGB1 axis.	Papaverine	62-72	MOK protein kinase	Rattus norvegicus	141-145
32842806-0	2020	Papaverine Has Therapeutic Potential for Sepsis-Induced Neuropathy in Rats, Possibly via the Modulation of HMGB1-RAGE Axis and Its Antioxidant Prosperities.	Papaverine	0-10	MOK protein kinase	Rattus norvegicus	113-117
32842806-11	2020	Considering its anti-inflammatory and antioxidant properties, papaverine"s neuroprotective effects possibly stem from the suppression of the RAGE-HMGB1 axis.	Papaverine	62-72	high mobility group box 1	Rattus norvegicus	146-151
32665909-7	2020	Dipyridamole- and papaverine-based aerosols have the ability to produce beneficial effect on the entire body"s immune system by stimulating the division of pluripotent CD34 cells.	Papaverine	18-28	CD34 molecule	Rattus norvegicus	168-172
32587621-6	2020	PDE10A inhibition by papaverine diminished osteogenic differentiation.	Papaverine	21-31	phosphodiesterase 10A	Homo sapiens	0-6
32587621-7	2020	While applying mechanical strain via cyclic stretching of hMSCs led to an upregulation of PDE10A gene expression, inhibition of PDE10A using the drug papaverine repressed expression of mechanoresponsive genes.	Papaverine	150-160	phosphodiesterase 10A	Homo sapiens	128-134
31100066-3	2019	Previously, we identified an inhibitor of HMGB1/RAGE interaction, papaverine (a non-narcotic opium alkaloid), using a unique drug design system and drug repositioning approach.	Papaverine	66-76	high mobility group box 1	Homo sapiens	42-47
31791357-11	2019	In addition, PAP elevated intracellular cAMP levels and CREB phosphorylation.	Papaverine	13-16	cAMP responsive element binding protein 1	Mus musculus	56-60
31810939-3	2019	Previously, we identified an anticancer candidate, papaverine, that inhibited the HMGB1-RAGE interaction.	Papaverine	51-61	high mobility group box 1	Homo sapiens	82-87
31810939-3	2019	Previously, we identified an anticancer candidate, papaverine, that inhibited the HMGB1-RAGE interaction.	Papaverine	51-61	long intergenic non-protein coding RNA 914	Homo sapiens	88-92
31100066-3	2019	Previously, we identified an inhibitor of HMGB1/RAGE interaction, papaverine (a non-narcotic opium alkaloid), using a unique drug design system and drug repositioning approach.	Papaverine	66-76	advanced glycosylation end-product specific receptor	Homo sapiens	48-52
31100066-5	2019	HMGB1 supplementation in the culture medium promoted tumor cell growth in T98G cells, and this effect was canceled by papaverine.	Papaverine	118-128	high mobility group box 1	Homo sapiens	0-5
31100066-7	2019	As an HMGB1/RAGE inhibitor, papaverine also significantly inhibited cell proliferation in U87MG and T98G cells.	Papaverine	28-38	high mobility group box 1	Homo sapiens	6-11
31100066-7	2019	As an HMGB1/RAGE inhibitor, papaverine also significantly inhibited cell proliferation in U87MG and T98G cells.	Papaverine	28-38	advanced glycosylation end-product specific receptor	Homo sapiens	12-16
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	Papaverine	124-134	tumor necrosis factor	Rattus norvegicus	171-180
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	Papaverine	124-134	interleukin 1 beta	Rattus norvegicus	185-193
30852743-6	2019	It was found that the level of MEK phosphorylation was upregulated after LPS stimulation, which was blocked by 10 mug/ml of papaverine.10muM U0126 significantly inhibited TNF-alpha and IL-1beta and increased IL-10 transcription and expression in retinal microglia (P &lt; 0.01).	Papaverine	124-134	interleukin 10	Rattus norvegicus	208-213
30852743-8	2019	Papaverine may inhibit inflammatory factors and promote the expression of anti-inflammatory factors through the cAMP/PKA and MEK/Erk pathway, thereby inhibiting LPS-induced activation of primary retinal microglia, and the MEK/Erk pathway may be partially regulated by cAMP/PKA, which can provide theoretical basis and experimental basis for its protection of the central nervous system.	Papaverine	0-10	Eph receptor B1	Rattus norvegicus	129-132
30852743-8	2019	Papaverine may inhibit inflammatory factors and promote the expression of anti-inflammatory factors through the cAMP/PKA and MEK/Erk pathway, thereby inhibiting LPS-induced activation of primary retinal microglia, and the MEK/Erk pathway may be partially regulated by cAMP/PKA, which can provide theoretical basis and experimental basis for its protection of the central nervous system.	Papaverine	0-10	Eph receptor B1	Rattus norvegicus	226-229
30826057-0	2019	Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.	Papaverine	0-10	high mobility group box 1	Mus musculus	41-66
30826057-0	2019	Papaverine identified as an inhibitor of high mobility group box 1/receptor for advanced glycation end-products interaction suppresses high mobility group box 1-mediated inflammatory responses.	Papaverine	0-10	high mobility group box 1	Mus musculus	135-160
30826057-5	2019	Papaverine was found to directly inhibit HMGB1/RAGE interaction.	Papaverine	0-10	high mobility group box 1	Mus musculus	41-46
30826057-5	2019	Papaverine was found to directly inhibit HMGB1/RAGE interaction.	Papaverine	0-10	advanced glycosylation end product-specific receptor	Mus musculus	47-51
30826057-8	2019	Taken together, these findings indicate that papaverine could become a useful therapeutic against HMGB1/RAGE-mediated sepsis and other inflammatory diseases.	Papaverine	45-55	high mobility group box 1	Mus musculus	98-103
30826057-8	2019	Taken together, these findings indicate that papaverine could become a useful therapeutic against HMGB1/RAGE-mediated sepsis and other inflammatory diseases.	Papaverine	45-55	advanced glycosylation end product-specific receptor	Mus musculus	104-108
30665449-10	2019	Both BTX-A and papaverine inhibited the maximum contractile effect of ET-1 to the same extent at the 0th hour; but, the inhibitory effect of BTX-A was significantly stronger at the 2nd hour (p &lt; 0.05).	Papaverine	15-25	endothelin 1	Homo sapiens	70-74
30195457-6	2019	Furthermore, the intraoperative use of papaverine improved the success rate of free flap transfer (P=0.015).	Papaverine	39-49	arachidonate 5-lipoxygenase activating protein	Homo sapiens	84-88
30704052-12	2019	Administering these drug combinations (i.e., avastin and papaverine, and avastin and QNZ) led to significant reductions in proliferation and mTOR activity of the aggressive DLD1 colon cell line in mice.	Papaverine	57-67	mechanistic target of rapamycin kinase	Homo sapiens	141-145
30665449-11	2019	In high concentrations, when we compared the effects of BTX-A (10- 6 M) and papaverine (10- 4 M) on 5-HT, papaverine showed stronger inhibition (p &lt; 0.05), whereas both agents had similar action of inhibition on ET-1 mediated maximum contraction responses.	Papaverine	106-116	endothelin 1	Homo sapiens	215-219